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Abstract
LncRNAs, recently found to be pervasively transcribed in the genome, can play key
roles in epigenetic modifications during gene transcription. Although, lncRNAs have no coding
potential they can regulate various biological processes. Their role in diabetic complications are
however not clear.
Using array analysis, we identified alterations of two lncRNAs in high glucose
(25mM/L,HG) treated retinal endothelial cells (HRECs). We validated upregulations of
lncRNA, ANRIL and downregulation of H19 in HRECs following incubation in HG. ANRIL
expressions were further measured with or without siRNA knockdown in ECs. ANRIL
knockout (KO) mice with or without streptozotocin (STZ)-induced diabetes were also
investigated for mRNA and protein expression of VEGF and ECM proteins FN and Col1α4.
ANRIL knockdown prevented glucose-induced increased VEGF, FN and Col1α4 levels.
Comparable results were observed in the retina, heart and kidneys of diabetic ANRILKO mice
compared to wildtype controls. Furthermore, ANRILKO had a protective effect on diabetesinduced renal functional changes. We further showed that these alterations under ANRIL’s
regulation are mediated by p300 and enhancer of zeste 2 (EZH2) of the PRC2 complex.
We also investigated the role of H19 in diabetes by silencing or overexpressing H19 in
ECs exposed to various glucose levels. We extended our study to H19 knockout (KO) mice and
vitreous samples from patients with proliferative DR. In both instances, diabetes caused
downregulation of H19 expression. The cells and retinal tissues from animals were examined.
H19 overexpression prevented glucose-induced endothelial-mesenchymal transition (EndMT)
through TGF-β in a Smad-independent pathway. Additional experiments showed a regulatory
relationship between ANRIL and H19.
These data suggest that glucose and diabetes cause alteration of specific lncRNAs in ECs
and mouse tissues respectively. This led to increased production of vasoactive factors and ECM
proteins; and alteration of cellular phenotypes to facilitate vascular remodeling and other
changes in diabetic complications. Identification of such mechanisms help in a better
understanding of the pathologies in diabetes and consequent development of RNA based
therapies.
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Chapter 1
1 General Introduction
1.1 Diabetes
Diabetes is a chronic disease caused by lack of sufficient insulin production by the pancreas or
when the body cannot effectively utilize the produced insulin leading to elevated blood glucose
known as hyperglycemia. The ancient Egyptians first recognized diabetes in 1500 B.C.E as a
condition where a person excessively urinates and loses body weight. It’s two types (later Type
I and Type II diabetes) were described by ancient Indian physician, Sushruta, and the surgeon
Charaka (400-500 C.E) but its association with elevated glucose wasn’t discovered till the late
1700s (1). The prevalence of diabetes has increased drastically over the past three to four
decades resulting in the elevation of diabetes to one of the most common and serious medical
conditions faced by mankind today. According to the World Health Organization, the diabetic
population has risen from 108 million in 1980 to 422 million in 2014, with numbers rising
rapidly in middle and low-income countries (2). Overall diabetes caused 1.6 million deaths in
2015 and is a major cause of kidney failure, blindness, heart attacks, strokes and lower limb
amputations (3).
Diabetes is comprised of various metabolic conditions involving cell’s inability to transport and
utilize glucose. The two major types are: Type 1 (T1D)- is due to insufficient insulin production
caused by T-lymphocyte mediated autoimmune destruction of pancreatic β-cells, Type II
(T2D)- is due to insulin resistance leading to compensatory β-cell hypertrophy. Other types
could manifest during pregnancy, drug/chemical toxicity, genetic disorders, insulin receptor
disorders and in association with pancreatic exocrine disease (4). Both T1D and T2D are
characterized by chronic hyperglycemia, resulting in various secondary complications including
kidney failure, neuropathy, peripheral vascular diseases, cardiac failure as well as retinopathy
(5). Therefore, modern medical care lays emphasis on various interventions aimed at controlling
the blood glucose levels, aimed at reducing the likelihood of chronic complications.
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1.2 Diabetic complications
Pathophysiological changes in diabetes contribute to hyperglycemia resulting in disrupted
cellular glycolysis and pyruvate oxidation (6). Chronic hyperglycemia and acute glucose
fluctuations result in the onset and progression of several secondary complications including
nephropathy, retinopathy, cardiomyopathy and neuropathy (7-11).

1.2.1 Diabetic Retinopathy
Diabetic retinopathy (DR) is the most common cause of blindness in individuals over 50 and
affects 1 in 3 persons with diabetes (12). DR was first detected in the 19th century using an
ophthalmoscope. It is a chronic vascular complication characterized by low-grade
inflammation, serum leakage through microvasculature, loss of capillaries and increased
vascular permeability ultimately leading to neovascularization (13,14).
Initially, hyperglycemia contributes to gradual biochemical and cellular alterations. During this
period, vascular alterations surface, accompanied by elevated mitochondrial and extracellular
reactive oxygen species (ROS) production injuring endothelial cells (ECs), pericytes and
neuronal tissues. These events are accompanied by localized hypoxia due to blockage of retinal
capillaries and release of angiogenic growth factors. As the disease progresses leaky blood
vessels become prominent resulting in macular edema (non-proliferative). Progression of this
process results in proliferative diabetic retinopathy (PDR), characterized by angiogenesis with
tufts of highly permeable new weak blood vessels on the surface of retina. These vessels can
rupture easily allowing blood to leak out into the vitreous and compromise vision (15).
Recent research has suggested that retinal dysfunction in diabetes is associated with changes in
the retinal neurovascular unit (16). This unit is conferred with unique characteristics by the
retinal architecture. The inner retinal layers are in close proximity with the neurovascular units,
thereby aiding in oxygen and nutrient delivery, while the outer retinal layers support production
of electrochemical impulses in response to light stimulation (16). In DR, the whole retinal
neurovascular system is impaired causing loss of neurovascular coupling, neurodegeneration
and neuroinflammation that can be detected before the development of vascular damage (17).
2

These insights suggest addressing both vascular dysfunction and neural degeneration for
possible therapeutic interventions in DR.
Present day treatments for DR revolve around laser photocoagulation for macular edema and/or
proliferative disease and vitreo-retinal surgery for serious complications (18). Other approaches
that delay its progression include blood sugar management, reduction of LDL using statins,
blockade of renin-angiotensin system and newer methods of inhibiting angiogenesis and edema
using vascular endothelial growth factor (VEGF) and VEGFR inhibitors (15,19-21).

1.2.2 Diabetic Nephropathy
As the worldwide diabetic population continues to rise, advanced diabetic nephropathy (DN)
continues to be leading cause of end-stage renal failure (ESRD) (22). Clinical development of
DN is based on the level of urine albumin excretion (UAE) and decline in the glomerular
filtration rate (GFR) (23). For unknown reasons 20% to 40% of patients with diabetes develop
DN associated with microalbuminuria (>30 mg <300 mg albumin in the urine/day),
macroalbuminuria (>300 mg albumin in the urine/day), and subsequent progression to ESRD
(24,25).
The disease progression starts in the nephron where hyperfiltration and hyperperfusion leads to
hypertrophy and subsequent thickening of the glomerular basement membrane (26). Glomerular
hyperfiltration paves way to microalbuminuria, culminating in microalbuminuria and renal
failure (27). Once the nephropathy is established multiple mechanisms contribute to its
outcomes. These include hyperglycemia-induced hemodynamic changes such as activation of
vasoactive factors like renin–angiotensin–system (RAS) as well as genetic predisposition (28).
During the course of this process, the kidney undergoes functional derangement and structural
remodeling that alters various cellular events and activates signaling pathways. Interaction of
these pathways in a complex mechanism results in renal fibrosis, mesangial expansion,
glomerular hypertrophy, oxidative stress and tubular inflammation (29). The body responds by
releasing cytokines like transforming growth factor β1 (TGF-β1), further aggravating the
hemodynamic changes (30-32).
3

Prevention and treatment strategies for DN involve targeting the risk factors including
hyperglycemia, hypertension, smoking and dyslipidemia (33). Blood sugar control reduced the
risk of disease development at young age, but its long-term effect on rate of progression of
chronic kidney disease (CKD) is controversial (34, 35). Along with hypoglycemic effects,
metformin, sodium glucose transporter-2 (SGLT2) inhibitors, thiazolidinediones, glucagon like
peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have positive effects
on DN (36-40). RAS blockers and dietary salt restriction have been used to control blood
pressure in DN patients with increased UAE. RAS blockers impact GFR in DN patients,
decrease glomerular tuft pressure and inhibit cytokine overproduction (41). However, RAS
blockade has failed to fully prevent renal injury progression in T1D and may cause accelerated
disease progression in patients with advanced chronic kidney disease (42). Smoking plays a
huge role in DN progression and quitting is mandatory for both T1D and T2D patients (43).
Statins are important hypolipidemic treatment recommended for all DN patients as it reduces
risk of atherosclerotic heart diseases in CKD patients but have minimal effect on CKD
progression (41,44). However, these approaches are not effective for all diabetic patients or
have varying side-effects. The accumulating scientific evidence call for a change in plan, raising
the need for novel therapeutic strategies to prevent its development and progression of ESRD.

1.2.3 Diabetic Cardiomyopathy
Cardiovascular complications are responsible for majority of diabetes related morbidity and
mortality (45). Such complications include atherosclerosis, autonomic neuropathy and diabetic
cardiomyopathy (DCM). DCM causes structural and functional changes in the myocardium
independent of coronary artery disease and hypertension (46). Rubler and colleagues first
described ventricular dysfunction occurring in diabetic patients in 1972 (47). Alterations in
myocardial structure, calcium signaling and metabolism are primary features that precede
accelerated left ventricular hypertrophy and increase susceptibility to ischemic injury and heart
failure (HF) (48).

Myocardial tissue undergoes structural and functional modifications in

diabetes induced by hyperglycemia, hyperlipidemia and insulin resistance (49). A histological
trademark of DCM is interstitial and perivascular fibrosis, characterized by increased deposition
of collagen accompanied by crosslinking of these collagen fibers contributing to reduced
4

ventricular compliance (47,50-51). Myocardial fibrosis is accompanied by left ventricle
hypertrophy (LVH). LVH has been linked to elevated serum markers of systemic inflammation
like fibrinogen, C-reactive protein and microalbuminuria (52). These structural changes are
accompanied by functional alterations namely diastolic and systolic dysfunction. Diastolic
dysfunction is defined as defective ventricular relaxation leading to pressure increase and
impairment in blood filling during diastole (49). During systolic dysfunction, the myocardium
fails to eject adequate blood volume, but is observed at later stages in DCM after subsequent
diastolic dysfunction has been established in the patients (53,54). Early identification of these
abnormalities is important to provide appropriate treatment and prevent advancement to HF.
Multiple mechanisms have been proposed to explain the pathogenesis of DCM. These include
autonomic dysfunction, defects in lipid metabolism, abnormalities in ion homeostasis,
alterations in structural proteins, increased oxidative stress, interstitial fibrosis and alterations in
myocardial substrates and energy metabolism (55-60). As compensation for glucose
assimilation, fatty acid transporters are increased to generate ATP through fatty acid (FA)
degradation (59). However excess FAs accumulate in cytosol and causes lipotoxicity through
generation of diacylglycerol and ROS. Hyperglycemia also triggers ROS and advanced
glycation end-product (AGE) production culminating in cardiac gluco-toxicity. Lack of fuel and
lipo/gluco-toxicity triggers cardiac inflammation, fibrosis and contractile dysfunction (61). In
response RAS and TGF-β systems mediating cytokine/ chemokines responses are significantly
enhanced (62).
Currently there is no single therapy for treating diabetic cardiomyopathy. Treatment options
centers around dietary glycemic control, direct and indirect regulators of fatty acid metabolism,
and inhibitors of factors triggering heart failure (53,63). Medical advancements and lifestyle
interventions have contributed to reduction in cardiovascular mortality in diabetic patients.
However epidemiological studies show higher incidence of diabetic cardiomyopathy despite
adjustments for hypertension, microvascular diseases, hypercholesterolemia, body mass index
and other factors (64-66).
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1.3 Pathogenesis: Mechanism of diabetic complications
Hyperglycemia is the central event leading to these micro- and macrovascular pathologies in
diabetes. Four distinct mechanisms have been proposed to explain the underlying effect of
hyperglycemia. These are: increased polyol pathway flux, increased levels of AGE, activation
of protein kinase C (PKC) isoforms as well as enhanced hexosamine pathway (67). Polyol
pathway is a less frequent route for glucose metabolism under normal conditions.
Hyperglycemia mediates increased conversion of glucose to polyalcohol sorbitol mediated by
aldose reductase, the first enzyme in this pathway (68). This is accompanied by decrease in cofactor NADPH essential for regenerating reduced glutathione (GSH), resulting in intracellular
oxidative stress (69). Intracellular hyperglycemia is a key accelerator of intracellular and
extracellular AGE formation (70,71). The intracellular AGEs then functionally alter
intracellular proteins, modify binding properties of extracellular matrix proteins (ECM) and
facilitate binding of AGE precursor-modified plasma proteins to AGE receptors on endothelial
and mesangial cells. These events then aid in activating the production of ROS (67). Majority of
the PKC isoforms are activated by diacylglycerol (DAG) which are elevated during
hyperglycemia (72). These isoforms are responsible for numerous effects such as elevated
levels of vasoconstrictors like endothelin-1 (ET-1), permeability factors like VEGF,
microvascular matrix proteins like, fibronectin and type IV collagen (Col1α4) as well as TGFβ1 (73). In addition, they also contribute to activation of nuclear factor-kB (NF-kB) and
NAD(P)H oxidases whereas bioavailability of nitric oxide (NO) and endothelial nitric oxide
synthase (eNOS) expression are reduced (73-76). Increased utilization of excess glucose by the
hexosamine shunt pathway also contribute to pathogenesis of diabetic complications (DC) (77).
This event mediates increased transcription of key genes such as TGF-β1 in arterial ECs and
plasminogen activator inhibitor-1 (PAI-1) in vascular smooth muscles, through a 4-fold increase
in O-GlcNAcylation of the transcription factor Sp1 (78-79). These mechanisms once thought to
be independent of each other are currently known to reflect a single hyperglycemia-induced
phenomenon; namely the over production of superoxide by mitochondrial electron transport
chain (MTETC) (80). Elevated levels of glucose in ECs in diabetes increase the flux of electron
donors (NADH and FADH2) into the MTETC and subsequently lead to voltage gradient across
mitochondrial membrane rising above critical threshold (81). Crossing the threshold leads to
increased superoxide formation and high levels of ROS. Mitochondrial superoxides produced
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due to hyperglycemia further activate the above-mentioned pathways by inhibiting
glyceraldehyde-3 phosphate dehydrogenase (GAPDH). Inhibition of GAPDH increases the
intracellular levels of glucose by deregulating glycolysis. The accumulating GAPDH shuttles
into the nucleus and gets modified by activated poly (ADP-ribose) polymerase (PARP). PARP
usually resides in the nucleus in an inactive form and gets activated when increased ROS
production in the mitochondria induces DNA strand breaks (82). PARP modified GAPDH is
reduced in activity leading to intracellular AGE formation, activation of PKC and hexosamine
pathway flux. The pathways then alter cell signaling by triggering various transcription factors,
inflammatory markers, cytokines and growth factors leading to further cell damage in multiple
ways (72,83-84). In the following sections I will describe specific mechanisms, which are of
direct relevance to this research.

1.4 Cell Signaling in diabetic complications
Signaling abnormalities in various cell types contribute to the pathogenesis of DC. As ECs are
primary targets of these complications, we will focus on these cells. Alterations in both intraand intercellular signaling evolve slowly during the years while the disease progresses.
Hyperglycemia and possibly free fatty acid (FFA) levels are key factors implicated in the
activation of biochemical pathways, including stress-activated signaling pathways of NF-kB,
NH2-terminal Jun kinases/stress activated protein kinases (JNK/SAPK), p38 mitogen-activated
protein (MAP) kinase, ERK1/2 signaling, PKC signaling and others like PI3 kinase, Janus
kinase (JAK/STAT) and mTOR pathway activation (85-91). One of the intracellular pathways
most extensively studied as a target of hyperglycemia and oxidative stress, is transcription
factor NF-kB (92). In the cytoplasm of unstimulated cells NF-kB exists as a latent dimer bound
to IkB. On activation by factors like oxidative stress, NF-kB dissociates from IkB and
translocate into nucleus where it binds to kB elements in the promoter region of certain genes
and affects gene expression (93). NF-kB plays key roles in inflammatory responses ultimately
leading to enhanced fibrosis especially in the kidneys; and regulates expression of large number
of genes, including those involved in DC such as VEGF (94-96). Many of these factors, in turn,
activate NF-kB, thereby initiating a vicious cycle. High glucose exposure on cultured ECs can
activate number of protein kinase family members, especially PKC (97-98). Isoform βII of PKC
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shows highest induction in the retina and heart of diabetic animals (99). PKC activation
involves increased DAG levels which are observed to be elevated in high glucose treated
vascular cells as well as retina of diabetic animals (99-100). Activation of PKC directly or in
concert with other intracellular signaling proteins can cause number of effects such as mediating
glucose-induced EC permeability, enhance ECM production, regulate cellular activity as well as
involvement in the expression of various growth and vasoactive factors such as VEGF (9798,101-104). Binding of VEGF to VEGF receptors causes release of DAG, and this increase in
DAG in turn leads to selective activation of PKC isoforms which mediate vasoregulatory roles
of VEGF such as permeability (105-106). VEGF also has critical effects on the physiology and
pathophysiology of podocytes, which is the main source of renal VEGF (107). Secreted VEGF
facilitates autocrine activation of podocytes, thereby inducing podocyte glomerular basement
membrane matrix protein production; e.g. α3(IV) collagen synthesis via PI3K signaling (108).
Further evidence suggests that accelerated glomerular angiogenesis may contribute to diabetic
glomerular hypertrophy and ECM expansion (109). Although VEGF receptors are present on
podocytes and mesangial cells, VEGF’s effect of DN results largely from endothelial signaling
leading to enhanced endothelial growth and proliferation as well as increase in permeability;
possibly through subsequent activation of MAPK pathway (110-111).
One of the crucial steps in the progression of DR is thickening of basal lamina (BL) that
surrounds ECs and pericytes of the retinal capillaries (112-114). Disturbances in the balance
between synthesis and breakdown of ECM components induced by high intracellular glucose is
considered the main cause of BL thickening (115-118). In addition, various growth factors like
VEGF and transforming growth factor TGF-β, may play a more direct role in this balance
disturbance (119-120). Excessive ECM deposition also occurs in the heart muscles
accompanied by abnormal proliferation of cardiac fibroblasts (121). Cardiac fibrosis is
characteristic of DCM and TGF-β is one of the most studied mediators of this phenomenon
(122-123). Numerous studies have reported high-glucose mediated elevation in the transcription
of TGF-β genes, thereby increasing the levels of the protein and its downstream signaling (124125). In addition to its role in the canonical SMAD signaling pathway, TGF-β is also the key
stimulator of three known MAP pathways namely; ERK, JNK and p38 pathways (126-128).
ECM protein deposition leading to glomerulosclerosis and renal hypertrophy are characteristic
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features of DN (129). Clinical studies suggest that responses triggered by TGF-β are involved in
pathways leading to interstitial fibrosis and glomerulosclerosis observed in ESRD (130).
Evidently, TGF-β is the chief cytokine in the regulation of ECM synthesis and is responsible for
stimulating the production of its components including proteoglycans, fibronectin and collagen,
while blocking matrix degradation (131).

1.4.1 Extracellular matrix proteins in diabetic complications
Chronic diabetes leads to structural and functional alterations in the vasculature. Modifications
to ECM and basement membrane (BM) thickening are the structural hallmarks in the target
organs of DC (132). First recorded by Siperstein and colleagues in 1968, these disturbances of
ECM are directly linked to loss of function in the target organs (133). ECM encompasses an
insoluble network of collagens, fibronectin, elastins, structural glycoproteins, proteoglycan
hyaluronans and integrins that provide cells with mechanical support and mediate multifarious
interactions between cells or cells and ECM of the vascular tissues (134). Excessive ECM
deposition in the glomerular matrix and tubulointerstitium is associated with significant decline
in the renal function during diabetes (135-136). As mentioned earlier ECM level depends on the
balance between synthesis and degradation. Elevated glomerular basement membrane thickness
in the glomeruli and the tubular system is seen in both T1D and T2D. Interstitial fibrosis and
atrophy of the tubules follow these glomerular changes. The interstitium harbors inflammation
and in the advanced stages of DN, glomerulosclerosis is prominent with a substantial
accumulation of ECM in the mesangium accompanied by reduced capillary volume (137). In
the retina, ECM provides a framework on which the cells reside and hence contributes to
structural integrity and the vasculature. Here, it functions as a cell attachment substratum,
promotes wound healing and enables intracellular communication among other functions (138140). The cardiac ECM consists of fibrillar collagen localized within myocardial interstitium
and non-fibrillary collagen as well as fibronectin and laminin in the myocyte basement
membrane (141-142). With the progression of diabetes, left ventricle might hypertrophy with
occurrence of hypertension-induced diastolic dysfunction (143-144). DCM is characterized as
cardiac dysfunction and alterations to vascular ECM are accompanied by various cardiovascular
complications. Regulating ECM composition by transforming growth factors and VEGF9

mediated angiogenic responses are compensatory responses to sustained EC damage by
hyperglycemia (145). ECM breakdown and formation plays pivotal roles in angiogenesis. It can
mobilize angiogenic growth factors to provide cues for directional growth of ECs.

1.4.2 Vascular endothelial growth factor in diabetic complications
VEGF is a vital part of tissue growth and organ repair segment of angiogenesis (new blood
vessels sprouting from pre-existing vasculature) and vasculogenesis (new blood vessel
formation) (146). Angiogenesis or neovascularization includes migration and proliferation of
endothelial and smooth muscle cells, ECM breakdown, pericyte and macrophage accumulation
and development of new vasculature (147). VEGF was discovered in 1983 by Senger, Dvorak
and colleagues as a key mediator in angiogenesis (148). Subsequent isolation, cloning and
clinical studies provided evidence for its critical role in occular neovascularization (149-151).
Diabetes is closely linked to impaired neovascularization and anomalies associated with it
includes increased angiogenesis in the retina and blood vessel walls, impaired wound healing,
defective release and function of endothelial progenitor cells from bone marrow and increased
production of angiogenesis inhibitor, angiostatin (152-154). Although VEGF plays a central
role in the development of pathological microvascular complications such as DR, it is also
essential for the survival of ECs, enhances microvascular permeability and is a potent
vasodilator (155-157). In DR, VEGF is important for proliferative DR as well as diabetic
macular edema (158). It alters retinal capillary permeability by enhancing protein
phosphorylation and increases EC proliferation by activating MAP proteins (159-160). It also
stimulates ECs to release matrix metalloproteinases leading to degradation of BM, in turn
allowing for cell migration (161). The proliferation and migration of ECs are followed by
synthesis of new BMs. These BMs have new capillaries which are stabilized by recruitment of
pericytes and other growth factors to the site (162). Microvascular abnormalities in heart can
cause ischemia in the absence of coronary atherosclerosis, leading to adverse cardiovascular
events in diabetes. DCM is characterized by these microvascular abnormalities in the absence of
coronary disease and leads to progressive heart failure (163-164). They are influenced by
angiogenesis factors, especially VEGF, in response to hyperglycemia and ischemia (165).
Impairments in VEGF expression and action have been observed to occur in diabetic patients
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(166-168). Glucose plays a significant role in DN pathogenesis and evidence suggests its direct
and indirect stimulation of VEGF expression in podocytes through TGF-β (169-170). Glucose
also increases TGF-β expression in podocytes and mesangial cells, which thereby stimulates
glomerular basement membrane (GBM) thickening and glomerulosclerosis through VEGF
(169-170). VEGF in turn inhibits TGF-β expression through negative feedback mechanism.
VEGF signaling affects GBM thickening, slit pore density and the quantity of nephrin, a protein
required for proper functioning of the renal filtration barrier, which are all related to the extent
of diabetic albuminuria (171). Obvious upregulation of VEGF in glomerular epithelial cells is a
sign of early DN, while its increase in the proximal tubules mark a more progressed stage (172).
VEGF in the glomeruli is important in DN development and the rise in glomerular VEGF
speeds up DN progression to advanced stages (172).

1.4.3 Endothelial-mesenchymal transition in chronic diabetic complications
The entire circulatory system is lined by ECs, forming a boundary between circulating blood in
the lumen and vessel walls from heart to small capillaries (173). They allow the blood to be
pumped farther by reducing turbulence of flow and unambiguously play critical roles in
maintaining overall homeostasis (173-174). The endothelium secretes several factors that
regulate coagulation, fibrinolysis, platelet aggregation and vascular tone (174). Hyperglycemia
causes the endothelium to be exposed to a range of negative intracellular occurrences that
promote endothelial dysfunction, where the endothelium loses it physiological properties (174).
Accumulation of fibrous connective tissue and excess ECM production in and around inflamed
or damaged tissue, that culminates in organ failure or death is one of the consequences of
endothelial dysfunction (175-178). Fibrosis involves proliferation of local fibroblasts and their
differentiation into myofibroblasts (178). Myofibroblasts, in comparison to fibroblasts have
elevated α-smooth muscle actin (α-SMA) and upregulated production of ECM proteins like type
IV collagens (178-179). Initially the origin of these myofibroblasts was thought to be local
proliferation of resident fibroblasts in response to factors like TGF- β, but subsequent research
suggests other cellular sources such as ECs (180-181). ECs can adopt mesenchymal phenotype
and express markers characteristic of myofibroblast differentiation such as α-SMA, smooth
muscle 22α (SM22α), vimentin, fibroblast specific protein 1 (FSP1) and ECM proteins like
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fibronectin and collagen and downregulate EC markers such as vascular endothelial cadherin
(VE-Cadherin) and cluster of differentiation 31 (CD-31) (181-183). This phenomenon is known
as endothelial-mesenchymal transition (EndMT) through which ECs gain an altered
differentiated phenotype and obtain invasive and migratory abilities (173). At the cellular level,
EndMT can be defined as loss of cell adhesion and actin reorganization to convert apical-basal
polarity to front-end back end polarity resulting in change from compact, well-structured
cobblestone-like shape to less organized spindle-shaped cells (183-184). The major regulatory
cytokines that stimulate EndMT belong to TGF- β superfamily of proteins including TGF-β1
and TGF-β2 (181,184-186). Importance of this major regulator in the activation of EndMT has
been described in several studies (187). TGF promotes EndMT through Smad-dependent and
Smad-independent pathways like PKC (185,188). Several studies have shown that inhibition at
TGF-signaling at various stages have resulted in decrease or partial reduction in EndMT and
fibrosis in animal models (185,187,189). TGF-signaling plays important roles in myofibroblast
differentiation and ECM alterations favor myofibroblast transdifferentiation through altered
responses to mechanical stress or transduction of growth factor signals (181). TGF is also
responsible for induction of cardiac fibroblast transdifferentiation to myofibroblasts and
promotes cardiac fibrosis by inducing ECM protein synthesis and reducing collagenase
expression (190-191). Renal fibrosis, caused by aberrant ECM accumulation, have also been
linked to abnormal differentiation and proliferation of activated myofibroblasts (181,192-193).
Therefore, TGF-signaling and EndMT are major contributors to generation of myofibroblasts
that are key role players in the development of fibrotic diseases such as DCM or DN. Targeting
these pathways and their specific components in myofibroblasts can possibly lead to effective
anti-fibrotic therapies (181). There are several known inhibitors of EndMT including epigenetic
regulators such as microRNAs (miRNA) and histone acetylators (194-195). Our lab has
demonstrated that during DR and DCM, miRNA 200b (miR200b) modulates EndMT in concert
with histone acetylator, p300 through regulation of TGF-β mediated Smad signaling pathways
(196-197). Most miRNAs act through inhibition of TGF-β signaling although other ways of
miRNA action in regulating EndMT have also been recorded in literature (198-203).
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1.5 Epigenetic regulation in Diabetic Complications
The chronic nature of diabetes makes it a high-risk factor for development of many
complications like cardiovascular disorders, kidney damage and retinal deterioration.
Multifactorial causes can be ascribed to the development of these complications (204-206).
There is considerable evidence indicating that the interaction between genes and the
environment can influence an individual’s susceptibility to develop a chronic complication
(207-209). The environmental factors can alter signaling pathways and alter gene expression
through epigenetic modifications. Epigenetics is defined as the study of heritable changes in
gene expression that does not involve changes to underlying DNA sequence. This represents a
change in phenotype without a change in genotype that affects how cells read genes (210).
The chromosomal DNA is tightly packaged into chromatin, and its status between
transcriptionally “active” (euchromatin) and ‘inactive’(hetero-chromatin) in response to
extracellular signals are key aspects that regulate gene expression (211-213). Chromatin is
composed of subunits known as nucleosomes. Each nucleosome has an octamer of histones,
with two copies of histone proteins (H2A, H2B, H3 and H4), wrapped by 147 base pairs of
chromosomal DNA. Post-translational modification of these histones (PTHMs) alter their
interactions with DNA and represent one of the key epigenetic regulations (214-215).
Epigenetic regulations can lead to non-heritable or heritable effects. During non-heritable
changes, cells are able to respond fast to factors altered in the environment (216). Heritable or
long-term epigenetic effects occur in response to long acting stimuli and can be transmitted to
memory of the offspring cells (217,218). There are several components of epigenetic pathways.
PTHMs along with methylation of DNA, short noncoding RNAs (ncRNAs; for example, micro
RNAs (miRNAs) and long noncoding RNAs (lncRNAs) are all components of these pathways.

1.5.1 Histone modification
Histone methylation and acetylation are the most well characterized epigenetic marks
implicated in diabetes and its complications (219-220).
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Methylation: Histone methylation involves transfer of methyl groups from the methyl donor
S-adenosylmethionine (SAM) to amino acid residues (lysine, arginine and histidine) by histone
methyltransferases (221,222). Methylation at the arginine and lysine residues leads to either
activation or repression of transcription. Arginine residue methylation results in activation while
methylation at lysine can lead to activation or repression of transcription. Generally, H3K4
(histone 3 methylated at lysine 4), H3K36 and H3K79 are associated with transcriptional
activation and H3K9, H3K27 and H4K20 are seen in repressed regions (223). To add to the
complexity of this regulation, lysine residues can be mono-methylated (m1), di-methylated (m2)
or tri- methylated (m3). Furthermore, the specific action of methylases and demethylases
control chromatin accessibility to transcriptional enzymes and therefore influence protein
expression (224).
A recent study has showed that human ECs transiently exposed to high glucose, stimulated
transcriptional activation of NFkB-p65, followed by overexpression of inflammatory factors.
These alterations were attributed to Set7-dependent mono-methylation of H3K4 (225-226).
Reversal of oxidative stress through overexpression of ROS-scavenger enzymes prevented both
NF-kB activation and vascular inflammation (225-226).
Evidence suggests involvement of important histone modifications in gene regulation associated
with pathogenesis in DN. A gene expression study on DN-related genes in mouse and rat
models, showed increase in transcriptional activating methylation H3K4me2, coupled with
decreased levels of H3K27me3 levels (227). Silencing of histone methyltransferase SET7 in
mesangial cells (MC) attenuated TGF-β1-induced gene expression (228). TGF-β is implicated
in fibrosis and expression of these genes and others like cell cycle inhibitor p21 in renal cells,
which contribute to DN pathogenesis (229). High glucose treatments in rat MC led to similar
histone modifications at fibrotic and cell cycle gene p21 promoters (228). Recent results from
Finnish DN study reported linkage between the polymorphism in SUV39H2, gene encoding for
a histone methyltransferase and various diabetic microvascular complications, including
retinopathy.
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Recently our lab described regulatory roles of tri-methylation at lysine27 (H3K27me3)
catalyzed by H3K27me3 transferase EZH2 (PRC2 component) in DC (230). EZH2 is part of
PRC2 multimeric complex known to negatively regulate expression of genes including
miRNAs. Other components of PRC2 complex are EED, SUZ12 and RpAp46/48 and this
complex has been widely studied in tumor biology where increased EZH2 promoted VEGF
stimulation and subsequent angiogenesis (231-232).

Acetylation: Histone acetylation involves interplay between two families of enzymes to
transfer acetyl group to lysine residues (233). Histone acetyl transferases (HATs) utilize acetyl
CoA and catalyze transfer of acetyl groups to lysine. Histone de-acetyl transferases (HDACs)
oppose HATs and reverse lysine acetylation (234). HATs are grouped, based on sequence
homology, structural motifs and function (235). Over activity of HATs results in hyper
acetylated histones with neutralized e-amine positive charge on H3K and H4K N-terminal tails,
that obliterates interactions with negatively charged DNA backbone (236). Hyperacetylation
therefore favors euchromatin formation; allowing better access to DNA templates by RNA
polymerase and transcription factors. HDAC on the other hand removes acetyl groups from eamine groups, resulting in creation of heterochromatin and transcriptional silencing (237).
Enhanced ROS production has vital roles to play in the pathogenies of diabetic complication
especially in the development of endothelial dysfunction (77). Epigenetic regulation of ROS
generating genes can have important implications in understanding the mechanisms underlying
these complications. Recent research suggests regulatory roles of both HATs and HDACs on
several genes associated with endothelial dysfunction and inflammation in diabetes. Activation
of sirtuin 1 (SIRT 1) from the sirtuin family of HDACs reduces ROS formation, thereby
suppressing NF-kB activation and PARP cleavage (238). Similarly, HATs can also regulate
NF-kB transcription, resulting in alterations in the gene expression of inflammatory pathway
genes. High glucose treatment on monocytes resulted in increased transcriptional activity of
HATs CREB binding protein (CBP) and p300/CBP- associated factor (p/CAF) leading to
enhanced acetylation of histone lysine at the promoter regions of inflammatory genes and TNFα and rise in their expression (239). HATs-mediated increase in pro-inflammatory cytokines
were prevented by p300 blocker, curcumin treatment on human monocytes exposed to high
15

glucose by reducing HAT activity and acetylation of CBP/p300 complex (240). Increased
promoter histone lysine acetylation of inflammatory genes has also been described in
monocytes of T1D and T2D patients (241).
Li and colleagues recently reviewed the roles of HATs in DN and have reported that high
glucose-mediated elevation in HATs such as p300, CBP and p/CAF are accompanied by
activation of pro-inflammatory cytokines, fibrotic processes, ECM proteins and endothelial
function in DN through acetylation of histone and non-histone proteins like Smads, p53, SP1
and NF-kB (242). Available literature on DN also suggests that HDAC1, HDAC2 and HDAC5
modulate genes induced by TGF-β1 (243). TGF-β1, a key signaling molecule implicated in
fibrosis, increases acetylation at H3K by recruiting the HATs like transcriptional co-activator
p300 and CBP to the PAI-1 and p21 promoters (243). A chromatin immunoprecipitation (CHIP)
assay to study histone modifications at promoters for AGEs and PAI-1 showed increased active
marks (mostly acetylation) in the glomeruli of diabetic db/db mice versus non-diabetics (244).
Increased H3K9 acetylation at promoters of inflammatory genes is tightly linked to elevated
HbA1c levels and induction of DC (245). In our work with DC, we have previously shown
miR200b dependent increased production of p300 (246,247). Furthermore, glucose induced
upregulation of vasoactive factors like VEGF and endothelin 1 (ET-1) were prevented by
p300siRNA (247). Moreover, p300 and SIRT1 (HDAC) were shown to regulate each other
directly and indirectly in endothelial cells exposed to high glucose (248).
In DR, increased histone acetylation has been partly ascribed to lowering of HDAC activity as a
result of high glucose treatment on retinal cells. HDAC initiators and inhibitors, mitigated or
aggravated diabetes-induced histone acetylation and pro-inflammatory protein expression in
Müller glial cells, thereby confirming role of histone acetylation in the pathophysiology of DR
(249). Recent research has shown that HDAC1 and HDAC2 modulate expression of cardiac
hypertrophy genes (250). In DCM, HDAC3 exerts a pro-hypertrophic effect in diabetic mice by
reducing expression of a MAP kinase phosphatase, DUSP5 (251). However, additional work is
warranted to identify specific types altered and their molecular targets in chronic diabetic
complications.
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1.5.2 DNA methylation
Methylation of DNA occurs at position C5 of cytosine in CpG dinucelotides, mostly in the
promoter regions by DNA methyl transferases (DNMTs). The presence of symmetrical CpG
methylation marks on both DNA strands facilitates post-replicative maintenance of the DNA
methylation patterns (252). There are two key components in the DNA methylation machinery
of mammals, DNMTs which establish and maintain DNA methylation patterns, and methylCpG binding proteins (MBDs), involved in identifying the methylation marks (253). These
modifications usually repress gene expression by disrupting the binding of transcriptional
machinery to promoter or by recruiting co-repressors to the promoter site. The methylation
patterns on the DNA are established by DNMTs, DNMT3A and DNMT3B53 along with
DNMT3L54 (254). These patterns are maintained through cell division by the methyltransferase, DNMT1 (254). DNMTs are wide-spread and involve similar catalytic mechanisms
where the enzyme and the substrate base react to form a covalent reaction intermediate (255).
All DNMTs use SAM as the methyl donor and transfers the methyl group to positon 5 on the
cytosine ring or amino group at position 6 of adenine (256). However, DNA methylation is not
an irreversible process. A family of protein known as Ten-eleven translocation (TET) are
actively catalyzing demethylation, primarily at the transcription factor binding sites (254).
Regulation of DNA methylation is associated with various human diseases including diabetes.
Alterations in DNA methylation of inflammatory genes, lipid and glucose metabolism genes as
well as those involved in oxidative stress have been reported in diabetes (257). Short-term high
glucose exposure to aortic endothelial cells led to promoter DNA methylation of NFkB-p65
(225). In streptozotocin (STZ)-induced diabetic rats, demethylation of liver X receptor α (LXR
α) a key regulator of macrophage function increased myocardial ventricular expression (258).
Another study in diabetic rats reported cell death of cardiomyocytes and DCM as a result of
altered methylation of p53-inducible p21WAF1/CIP1 promoter (259). In T2D patients with
DCM, demethylation of CpG islands in the Kelch-like ECH associated protein 1 (Keap1)
promoter increased Keap1 expression and targeted nuclear factor (erythroid-derived 2)-like 2
(Nrf2), a regulator of antioxidant proteins to proteosomal degradation (260). These studies
indicate that gene regulation by DNA methylation under high glucose environments may have
important roles in pathophysiology of DCM.
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Hyperglycemia mediated alterations of DNA methylation have also been reported in DN (261).
DNA methylation profiling of DN patients showed altered methylation of 1,061 genes (262).
Fibrotic and non-fibrotic kidneys isolated from animal models of kidney disease showed
aberrant hypermethylation at RASALI, induced by TGF-β1. It leads to increased Ras activation
in fibroblasts, leading to proliferation and fibrosis (263). ECs exposed to high glucose showed
altered DNA methylation of several genes involved in endothelial function (264). DNA
methylation profiling of genomic DNA from diabetic patients with or without DN, also showed
differential methylation of various genes, including UNC13B, that is known to mediate
apoptosis in glomerular cells exposed to hyperglycemia, indicating its association with initiation
and pathogenesis of DN (265).
Altered DNA methylation of several genes dysregulated in DR, have been observed in diabetic
patients and in vitro studies. A genome-wide analysis of DNA methylation in T1D patients
identified differential methylation of close to 233 unique genes in cases of PDR versus controls,
suggesting the prospects of this distinct methylation pattern as a marker for PDR (266). Matrix
metalloproteinase-9 (MMP-9) is known to be elevated in retina and capillary cells during
diabetes (267). Kowluru and colleagues showed that prevention of hypomethylation at the
MMP-9 promoter prevents mitochondrial damage in retinal ECs and tissues from diabetic
mouse retina (268). Persistent hypermethylation at the regulatory region of the catalytic subunit
of mitochondrial DNA (mtDNA) replication enzyme, affected its binding to mtDNA which was
associated with continued progression of DR in STZ-induced diabetic rats (269). These
aforementioned studies in ECs, animals and patients highlight the significant role of DNA
methylation in the pathophysiology of diabetes and its complications like DCM, DN and DR.

1.5.3 Non-coding RNAs
Genomics studies over the years have influenced the identification of potential drug targets for
validation. However, target validation does not promise a drug candidate. Regulation of gene
expression by controlling post-transcriptional modification is an expensive mechanism for the
protein-coding genes. Hence novel approaches that target the process at the transcriptional level
would save energy involved in RNA modification and subsequent protein production. Majority
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of the human genome sequences studied to date are protein-coding which comprises only 1.5%
of the entire genome (270). Recently focus has been drawn onto the remaining non-coding area
of the genome and its importance in normal development and relevance in diseases (271). These
ncRNAs when functional, exert regulatory activities independent of the protein encoding route.
Hence on manipulation, they constitute potential drug targets capable of phenotypic changes in
the organism (272). The potential roles of these ncRNAs are still baffling, although they are
known to play regulatory roles in various biological processes. For instance, miRNAs are a
category of short ncRNAs (< 22-nts) involved in multiple physiological and pathological
functions in the living system (273-275). On the other hand, lncRNAs are of larger size
(>200nts) which works through a variety of mechanisms.

1.5.3.1 Short non-coding RNA (miRNAs)
miRNAs (~20-25 nucleotide) are short RNA molecules that do not code for proteins. miRNAs
as synthesized through RNA polymerase II, processed to precursors in the nucleus by RNAse
III Dorsha and DiGeorge syndrome critical region 8 (DGCR8) and exported to cytoplasm by
exportin 5. They are further processed in the cytoplasm by Dicer into functionally active∼22 nt
double-stranded RNA molecules (miRNA duplex). Recent evidence show that the
thermodynamic stability of the duplex determines which strand is to be selected to be loaded
onto RISC (RNA-induced silencing complex) by Ago (Argonaute) proteins (276). Regardless of
the strand chosen, once loaded into RISC the miRNAs direct the complex to the target, based on
complementarity between the miRNA seed sequence and target transcript, culminating in
transcriptional repression of the target. Mechanisms of repression by miRNAs are diverse,
where a single miRNA can target multiple mRNAs or a single mRNA can by targeted by
multiple miRNAs (277). Presently, more than 2000 human miRNAs are listed in the miRBase,
and this huge number combined with the vast range of their targets make them candidates for
numerous functions (278). miRNAs play important roles in controlling histone modification
(277,279-280), in diverse cellular processes (281) and regulate lncRNAs (282). miRNAs are
implicated in number of diseases and have emerged has key regulators of specific aspects of
disease pathology in DC (283).
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Nephropathy is an important research area where most miRNA dysregulations have been
identified. Podocyte-specific deletion of Dicer was attributed to kidney failure and early death
(284,285). Abnormal expression of several miRNAs in cell lines and kidney of diabetic mice
emphasis importance of these molecules in renal fibrosis and DN. TGF-β1-treated murine
mesangial cells and mouse models of diabetes (T1D and T2D) showed elevation of several
miRNAs (miR192, miR200b/c, miR216a and miR217) in their renal glomeruli compared to
non-diabetics (286-289). However, another miRNA, miR-200a was decreased in TGF-β1treated proximal tubular epithelial cells (290). miR21 upregulated in T1D mice, could also
target PTEN and promote mTOR signaling; important components in DN. Other miRNAs
alterations were found in glomeruli of db/db mice as well as podocytes and renal endothelial
cells exposed to high glucose. These included miR93, miR29c, miR192 and miR200b
(291,292). To decipher their role in DR, an in-depth miRNA profiling of the retina and retinal
ECs in STZ-induced rats were conducted. The results showed upregulation of miRNAs
responsive to NF-kB (such as miR146, miR155, miR132 and miR21) and VEGF in the diabetic
samples versus controls (293). Our lab has also shown regulatory roles on miRNAs, miR146a
and miR200b in ECs treated with high glucose and retinas from diabetic mouse models. These
miRNAs were themselves reduced in a high glucose environment and regulated expression of
fibronectin and VEGF respectively, both mediated by increase in the co-activator p300
(294,246). Another miRNA, miR29b was upregulated in the early stage of diabetes in cells of
retinal ganglion cells and inner nuclear layer of retinas of STZ-induced rats versus normal
animals (295). The results indicate a protective role of miR29b against apoptosis of retinal
neurons in DR and can be considered with other miRNAs for intravitreal injections as therapy
for DR. Several studies have also focused on identifying miRNAs as therapeutic and diagnostic
tools for diabetic cardiovascular complications (296). DCM is the result of dysfunction in a
number of cells types in the heart such as vascular ECs, cardiomyocytes and myoblasts (297).
Along with these, there is an increased recruitment of M1 macrophage leading to elevated
cytokine levels in diabetic hearts (298). These cytokines along with transcriptional factors
mediate effects that result in cardiac hypertrophy and fibrosis (297). Many miRNAs have been
recognized in these processes including miR133, miR320, miR29, miR30, miR1, miR206 and
miR21 (299). We have demonstrated pathogenic roles of miR146a, miR200b, miR133a, miR
195, miR1, miR9 in glucose exposed ECs and in various chronic DC (300).
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1.5.3.2 Long non-coding RNA (lncRNA)
The vast span of non-coding regions brings us to question of its role in the cellular system,
especially the poorly understood lncRNAs. The idea of lncRNAs first surfaced some two
decades ago with the description of X-inactive specific transcript (XIST), the gene that is
responsible for X-chromosome inactivation in eutherian lineage and lacks an open reading
frame (301,302). They are defined as transcripts >200 nucleotides that may be transcribed by
RNA polymerase II or III, subjected to splicing or contain a single exon (303). On the basis of
their location and orientation relative to nearby genes they can be classified as sense/antisense,
divergent/convergent or intronic/intergenic (304). These tissue-specific RNAs tend to form
thermodynamically stable secondary and higher-order structures. Their myriads of roles include
modulation of alternate splicing, chromatin remodeling, cis/trans-acting regulators of gene
expression and RNA metabolism (305-309). Cis-acting lncRNAs mediate local genes while
trans-acting lncRNAs are involved with multiple targets (309). Dysregulation of target genes
leads to abnormal lncRNA expression responsible for cellular defects and disease progression
including carcinogenesis and neurodegeneration (271,310). MALAT1, lincRNA-p21, HOTAIR,
LSINCT5, PTCSC3 and H19 are some of the lncRNAs associated with various kinds of cancers
(311). Another lncRNA, CDKN2B-AS1 (ANRIL) has been linked to cancer, diabetes and
cardiovascular diseases (312). Along with cancer, GAS5 lncRNA has been linked to
autoimmune diseases (313).

Recent publications since 2012, has shown a significant increase in the focus of lncRNAs in
diabetes mellitus and its complications. In retinal samples from patients with early DR, 303
lncRNAs were found to be perversely expressed, of which 214 were downregulated and
remaining 89 were upregulated (314). Additionally, metastasis-associated lung adenocarcinoma
transcript-1 (MALAT1) that interacts with NF-kB, was significantly upregulated in retinas of
STZ-induced diabetic rats and db/db mice as well as in the aqueous humor of DR patients
(314,315). We have also reported MALAT1 levels to be elevated in high glucose-treated ECs
and diabetic kidneys, which regulated glucose-induced inflammatory cytokine production (316).
In DN, TGF-β activated Akt by stimulating the expression of miR-216a and miR-217 along
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with their host lncRNA, RP23, as well as miR192 and its host lncRNA, CJ241444 resulting in
p300 activation (288,317). These alterations resulted in mesangial cell proliferation and
hypertrophy. Another lncRNA, plasmacytoma variant translocation 1 (PVT1), was classified as
a candidate gene for ESRD in T2D and later found to be associated with ESRD in T1D as well
(318,319). Upregulated under high glucose conditions, PVT1 was revealed to be a regulator of
ECM, and targeted TGF-β1 and PAI-1 (320). DCM is a prominent cardiovascular complication
of diabetes and a few lncRNAs have been associated with DCM also. In a rat model of DCM,
Zhou and colleagues reported upregulation of lncRNA myocardial infarction–associated
transcript (MIAT) (321). Their recent work showed MIAT to function as competing
endogenous RNA to increase death-associated protein kinase 2 (DAPK2) through sponging of
miR22-3p, facilitating cardiomyocyte apoptosis in DCM (322). MALAT1 was shown to be
upregulated in cardiac tissues of diabetic rats and patients with myocardial infarction (323-325).
MALAT1 knockdown was able to reduce myocardial inflammation as a result of diabetes and
led to improved left ventricular function in the diabetic rats (323, 324). LncRNA H19 is
reported to have multiple mode of actions on cardiomyocytes exposed to high glucose. It can
bind and recruit EZH2 at the promoter of GTP-binding protein Di-Ras3 (DIRAS3), causing
inhibition of DIRAS3-mediated autophagy and imparting a protective effect of the
cardiomyocytes exposed to high glucose (326). H19 can also serve as a precursor to miR675
and post-transcriptionally regulate numerous target genes important for cell proliferation and
differentiation (327,328).

Implications of lncRNAs in diseases broaden the avenues for potential drug targets such as
antisense therapies. Although ncRNAs do not give any room for protein product manipulations
for therapy, use of techniques like siRNA has shown regulation of sense transcript expression
levels. Taking into account the long road ahead, these approaches could be useful in
overcoming a key problem in traditional therapies: development of drug resistance.

1.5.3.2.1 H19 lncRNA
Over the years several lncRNAs have been identified in mammals, but many of their biological
roles remain unknown. The H19 gene (also known as ASM; BWS; WT2; ASM1; D11S813E;
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LINC00008 and NCRNA00008) produces a 2.3kb spliced, capped and polyadenylated lncRNA
which is abundantly expressed in developing embryos and down-regulated after birth (329).
H19 was isolated by Tilghman and colleagues in 1984 while screening for genes upregulated by
α-fetoprotein in mice fetal liver (330). The paternally imprinted gene is conserved between
humans (Ch 11p15) and mice (Ch 7) but lacks a common open reading frame, ruling out
existence of proteins coded by this gene (329). Predominantly cytoplasmic, H19 is co-regulated
by Igf2 (Insulin-like growth factor 2); a maternally imprinted gene located on the same locus
(331). In the H19-Igf2 locus, a primary imprint is set on H19-ICR (imprinting control region)
during gametogenesis and secondary imprinting is established on Igf2-DMR (differentially
methylated regions) after fertilization (332). The two genes share endodermal and mesodermal
enhancers that regulate the promoter region activation.
H19 was one of the first lncRNAs to be well characterized since its discovery 20 years ago.
However most of its biological roles remain undeciphered. Speculations revolve around
potential functions as post-transcriptional regulator binding to certain proteins like Igf2 mRNAbinding proteins, or interaction with molecules like miRNAs through DNA methylation or
histone modification of DMRs (333,334).
H19 is known to harbor protumorigenic properties as ectopic H19 expression enhanced
tumorigenic property of carcinoma cells in vivo (335). Its carcinogenic properties have been
recently described in various cancers like bladder carcinoma (336), hepatocellular carcinoma
(337) and gliomas (338) although some research described tumor suppressor roles of H19 in the
initial stages of colorectal cancer (339) and other cancers (332). This gene has also been
implicated in genetic disorders like Beckwith-Wiedemann Syndrome (BWS) (340) and SilverRussell Syndrome (SRS) (341) as well as during gestational diabetes in mouse models
(342,343).
Dysregulation of H19 and other ncRNAs present pathological consequences through versatile
functional roles. Different ncRNAs including lncRNA and miRNAs may have close
relationships depending on their location and sequence similarity. This has become increasingly
evident in current research on functional roles of H19 where it is observed to interact with
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several miRNAs. These include; modulation of miR-let-7 in skeletal muscles (344), interaction
with its direct precursor miR-675 in gliomas (338) and regulation of miR-200 family in
hepatocellular carcinomas (337). Our lab has previously shown a novel miR200b mediated
regulation of histone acetylator, p300 in diabetic retinopathy (246). Hence, modulating H19
may potentially lead to correction of abnormalities in several molecules altered during different
DC, directly or through p300. In this study, we plan to elucidate the role of H19 in DR and its
interactions with members of miR200 family in DC. Such alterations will be studied using in
vitro and in vivo models of diabetes.

1.5.3.2.2 ANRIL lncRNA
The INK4/ARF locus on chromosome 9p21 was highlighted as the strongest genetic
susceptibility locus for cardiovascular disease (CVD) (345,346). Later it was associated with
other conditions such as type 2 diabetes (346, 347), Alzheimer disease (348), glaucoma
(349,350), endometriosis (351) and periodontitis (352). The CVD and diabetes-associated hotspot lies in a region overlapping a newly discovered lncRNA, ANRIL (antisense ncRNA in the
INK4 locus). However, the CVD-risk alleles have been associated with both, increased (353)
and reduced expression of ANRIL (354,355). ANRIL is also known as CDKN2B-AS1;
CDKN2B-AS; CDKN2BAS; NCRNA00089 and p15AS. ANRIL consists of 19 exons,
spanning 126.3kb. It produces a 3834bp RNA. It is situated in the p15/CDKN2Bp16/CDKN2A-p14/ARF gene cluster, in the antisense direction (312).
ANRIL’s

transcription

is

initiated

from

INK4A-ARF-INK4B

gene

cluster

and

it

represses INK4A, ARF and/orINK4B (355). ANRIL may have a direct transcriptional effect or
an indirect effect in association with a histone modifier and methylating agent, the member of
the multiprotein Polycomb Repressor Complex 1 and 2 (PRC1, PRC2). The PRC2 system
consists of many subunits (eg. EZH2, EED, SUZ12 and RpAp46/48), each having its own role
in maintaining and stabilizing PRC2 activity. These complexes are critical in the epigenetic
regulation of the CDKN2A/B locus (356). Moreover, histone modifications caused by
Polycomb proteins occur in coordination with other epigenetic mechanisms. Polycomb proteins
CBX7 and EZH2 interact with DNA methyltransferase DNMT3B and the activity of chromatin
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remodelers have shown to influence PRCs occupancy in the CDKN2A/B locus (356).
Furthermore, EZH2 bound and directly methylated transcription factor GATA4 is a key dose
sensitive regulator of heart development in mice and human (357,358). GATA4 methylation by
PRC2 proteins impaired its acetylation by histone acetylator, p300 resulting in reduced
transcriptional potency (359). Conversely, loss of PRC2 activity in embryonic stem cells
resulted in histone H3K27 acetylation catalyzed by acetyltransferases p300 and CBP (360).
Recently over expression of ANRIL has been shown to regulate p300 and hence might be a key
player PRC complex-p300/CBP mediated epigenetic modifications (361). Past research by us
and others have reported that VEGF, ECM proteins and other factors characteristically altered
in DC are regulated by p300 and specific miRNAs (196,197, 230,246,247,283,294). We have
also shown that miR200b regulates VEGF production by altering p300 levels and works
through PRC2 complex (230). We predict that ANRIL too may regulate important factors
elevated in DC through PRC2 complex with / without mediation by miR200 and p300. We hope
to decipher this regulatory role of ANRIL in DC.

Figure 1.1: An overview of the various processes at the cellular and molecular level during h
hyperglycemia. Glucose enters endothelial cells from blood. High levels of intracellular glucose
activate several pathways such as polyol pathway, hexosamine pathway, protein kinase C and
advanced glycation (AGE) pathways. These pathways increase superoxide production by the
mitochondrial electron transport chain, leading to oxidative stress. Oxidative stress thorough
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epigenetic regulators, activate expression of transcription factors like NF-kB as well as multiple
pathogenic molecules such as vascular endothelial growth factors (VEGF) and transformation
growth factors TGF-β. Downstream signaling from these molecules causes cellular damage in
diabetic complications.

1.6 Rationale
Microarray analysis of the long non-coding RNAs from microvascular ECs exposed to high
glucose (25mM) showed alterations of multiple lncRNAs (Fig 1.2). We specifically examined
two lncRNAs, ANRIL and H19 in this study due to their known interactions with key
epigenetic regulators of interest to us, namely the PRC2 complex, p300 and miR200b
(337,356,361). We have previously shown that these epigenetic regulators control diabetesinduced upregulation of VEGF and ECM proteins as well as cellular phenotypic alterations such
as EndMT. Furthermore, these lncRNAs are also known to be of importance in cardiovascular
diseases and diabetes (345-347, 326). In this thesis, we hope to decipher key regulatory roles of
ANRIL and H19 on these pathogenic changes through mediation by PRC2 complex, p300 and
miR200b. We identified alterations of ANRIL and H19 in the array analysis and validated such
changes by RT-PCR. As discussed above, lncRNAs may mediate their action directly or
indirectly through p300, miR200b or changing actions of PRC complex. Hence modulating
these lncRNAs may potentially lead to correction of abnormalities in several molecules altered.
In this study, we plan to elucidate the roles of ANRIL and H19 in diabetic complications,
possibly directly or through interactions with miR-200b and p300. We have previously shown
alterations of p300, miR200b and PRC methylation in multiple chronic diabetic complications.
Hence, based on our previous discussion and these preliminary findings we hypothesized that in
chronic diabetic complications lncRNAs ANRIL and H19 regulate production of key
pathogenic molecules and cellular phenotype changes through specific pathways.
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Figure 1.2: a) Volcano plot of differentially expressed lncRNAs in hyperglycemic versus
normoglycemic condition treated endothelial cells. Vertical lines correspond to 1.2-fold change
up and down, respectively, and the horizontal line represents a p-value of 0.05. Red points
differentially expressed genes with statistical significance. b) The pie chart shows potential
function of the lncRNAs altered in diabetes as detected by the array.

1.7 Central Hypothesis
In chronic diabetic complications, lncRNAs- ANRIL and H19 regulate production of key
pathogenic molecules and cellular phenotype changes through specific pathways.

1.8 Specific Aims
Aim 1: To elucidate the role of ANRIL in regulating VEGF in diabetic retinopathy
(Investigated in Chapters 2 of the thesis).
In this aim we examined the changes in the expression of ANRIL in human retinal endothelial
cells exposed to high glucose and retinal tissue from diabetic mice. Then we moved onto
unravelling the regulatory role of ANRIL on the expression of VEGF in a high glucose
environment. The last part of the study explores the mechanism of ANRIL’s action whether it
occurs through its interaction with miR200b, p300 and PRC2 complex.
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Aim 2: To investigate the regulatory role of ANRIL in upregulation of extracellular
matrix protein and VEGF in diabetic nephropathy and diabetic cardiomyopathy
(Investigated in Chapter 3).
This study explores the role of ANRIL, extending it to other diabetic complications namely the
kidneys and heart. Expression of ANRIL were measured in the kidneys and cardiac tissues. The
study further explores alterations of extracellular matrix proteins and VEGF under the influence
of ANRIL and examines whether these are mediated by p300 and PRC2 complex.
Aim 3: To examine the role of H19 in regulating endothelial-mesenchymal transition
during diabetic retinopathy. (Investigated in Chapter 4).
The expression of H19 in diabetic retinopathy is explored here. The study utilizes human retinal
endothelial cells exposed to high glucose and retinal tissue from diabetic mice and samples
from diabetic patients. The study aims to elucidate the role of H19 in regulating endothelialmesenchymal transition and the specific mediator pathways.
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2.1 Introduction
Diabetic retinopathy is the most common cause of blindness in individuals over 50 years of age,
affecting 1 in 3 persons with diabetes (1). It is a chronic vascular complication characterized by
low-grade inflammation, serum leakage through microvasculature, loss of capillaries, increased
vascular permeability and eventually neovascularization (2,3). Last decade has seen scientific
and medical progress on early diagnosis and prevention in order to combat this condition.
However, in this complication a variety of defects lead to functional and structural alterations in
the retina that remains a significant challenge (4).
Endothelial cells (ECs), the main target of hyperglycemic damage undergoes growth, increased
permeability, remodeling and phenotypic alterations in diabetes (5). Various vasoactive factors
are involved in angiogenesis as seen in diabetic retinopathy. However, vascular endothelial
growth factor (VEGF) signaling in ECs, represent a major rate-limiting step in this process (6).
Induced in response to increased oxidative stress, VEGF binds to and activates tyrosine kinase
receptors VEGFR-1 and VEGFR-2. Production of VEGF may however be regulated at
transcriptional and post-transcriptional levels (7-10).
Transcriptional regulation in mammalian systems is critically characterized by dynamic
switching between “active” and “inactive” states of chromatin in response to extracellular and
intrinsic signals. Such signals include histone and DNA modifications as major epigenetic
mediators, recently joined by several RNA molecules including microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs) (11,12). Advances in DNA/RNA sequencing techniques
have highlighted the existence of numerous noncoding RNA (ncRNA) molecules with
significant regulatory roles, impacting both physiology and diseases (13-16). In particular,
lncRNAs have been shown to be of importance in various biological process such as
transcription, translation, splicing, intracellular/extracellular trafficking, etc (17). Recent studies
have identified large and small-scale mutations affecting noncoding genomes. Mutations in
lncRNAs have been linked to diseases such as cancers, neurodegenerative diseases as well as
genetic disorders (18-23).
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A recent genome-wide study revealed existence of lncRNA ANRIL (Antisense RNA to INK4
locus). ANRIL has been noted to be significant in cardiovascular diseases, type 2 diabetes,
glaucoma, intracranial aneurysm and cancers (24-28). ANRIL consists of 19 exons, spanning
126.3kb and producing a 3.8bp RNA. It is situated in the p15/CDKN2B-p16/CDKN2Ap14/ARF gene cluster (29). ANRIL may have direct transcriptional effects or an indirect role as
a recruiter of chromatin remodeling complexes like polycomb repressor complex 2 (PRC2) to
specific genomic loci (30,31). Overexpression of ANRIL has also been shown to regulate
histone acetylator, p300 (32). Its role in epigenetic silencing of specific miRNAs have also been
reported (33).
We and others have previously shown that VEGF and other vasoactive factors are regulated at
the transcriptional level through p300 and specific miRNAs (34-36). We have also shown that
in diabetic retinopathy, microRNA 200b (miR200b) regulates production of VEGF directly or
through regulation of p300 and/or through PRC2 complex (8,9). ANRIL may work though
PRC2 complex, and in other systems has been shown to have a regulatory role on p300 (31,32).
Here, we examined the role of ANRIL in regulating VEGF production, its molecular
mechanism and action in diabetic retinopathy. These phenomena were studied in human retinal
endothelial cells (HRECs) exposed to various levels of glucose as well as in retinal tissues of
diabetic mice. We further investigated whether ANRIL facilitates such effects by regulating
miR200b in concert with PRC2 complex and p300.

2.2 Methods
All reagents were obtained from Sigma (Oakville, ON, Canada) unless otherwise specified.

2.2.1 Cells
We used human retinal endothelial cells (HRECs, Olaf Pharmaceuticals, Worcester, MA, USA),
grown in endothelial basal media-2 (EBM-2), supplemented with 10% fetal bovine serum. The
cells were plated at a density of 4.3x105 cells/mL. Following 24h incubation in serum-free
media (EBM-2), cells were incubated with various levels of D- glucose [5mM/L,normal glucose
(NG); 25mM/L,high glucose (HG)] or 25mM/L L-glucose, osmotic control (LG)] at 75% cell
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confluency as previously described (37). 3-Deazaneplanocin A (DZNEP) pre-treatment was
also carried out where needed (9). Each experiment was performed atleast in triplicates.

2.2.2 siRNA transfection
HRECs

were

transfected

(5nmol/L,Dharmacon,Chicago,IL)

with
or

LincodeTM
silencer

Human
siRNA

CDKN2B-AS1
CDKN2B-AS

siRNA
(5nmol/L,

Ambion,Austin,TX) using Lipofectamine2000 (Invitrogen, Burlington, ON, Canada).
Scrambled controls were used. The cells were transfected for 3h and recovered in full media
overnight. Cells were then incubated in media with various glucose levels as previously
described by us (9). Gene knockdown was verified by real time RT-PCR, which showed ≈70%
reduction of ANRIL expression (compared to scrambled control).

2.2.3 Animals
All procedures were conducted in accordance with the ARVO statement for the Use of Animals
in Ophthalmic and Vision Research. All animals were cared for according to the guiding
principles in the care and use of animals. Western University and Animal Care and Veterinary
Services approved the experiments. All experiments conform to the guide for care and use of
laboratory animals published by the NIH (NIH publication no. 85-23, revised in 1996).
ANRIL knockout (KO) mice with a 70kb deletion on Chr 4 [129S6/SvEvTac-Del(4C4C5)1Lap/Mmcd] corresponding to 58kb interval on chromosome 9p21 in humans, were used
(38). The ANRILKO mice were obtained from Mutant Mouse Resource & Research Centre
(MMRC, Davis, CA); and administered five doses of STZ intraperitoneally (50mg/kg in citrate
buffer, pH5.6) on alternate days. Age and sex-matched littermate controls received identical
volume of citrate buffer. Diabetes was confirmed by measuring blood glucose (>20mmol/L)
from tail vein using a glucometer. Animals were monitored for changes in body weight and
blood glucose. After 8 weeks of diabetes, mice were sacrificed and tissues collected.

2.2.4 Microarray
For lncRNA microarray analysis, HRECs were incubated with various levels of glucose.
Cellular RNA was extracted using RNA isolation kit (Ambion, Carlsbad, CA). Custom analysis
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of lncRNA expression profiling was performed by Arraystar Inc. (Rockville, MD).

2.2.5 RNA analysis
RNA was extracted with TRIzol reagent (Invitrogen) as previously described (37). cDNA for
PCR was synthesized using high-capacity cDNA reverse-transcription kit (Applied Biosystems,
Burlington, ON, Canada). Real time RT-PCR to detect mRNA expression was done in the
LightCycler (Roche Diagnostics). Housekeeping gene b-actin mRNA was used to normalize the
data.

2.2.6 miRNA analysis
MiRNA was isolated using mirVANA miRNA isolation kit (Ambion, Austin, TX) (8,34,37).
cDNA for PCR was synthesized with high-capacity cDNA reverse-transcription kit (Applied
Biosystems, Burlington, ON, Canada). Real time RT-PCR was performed with TaqMan
miRNA Assays (Applied Biosystems) in a LightCycler (Roche Diagnostics). miR-200b
expression levels were normalized to housekeeping gene U6.

2.2.7 ELISA
ELISA was performed to measure the expression of VEGF protein using a commercially
available kit (ALPCO, Salem, NH; R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions (34).

2.2.8 Tube formation assay
HRECs (1.5x104 per well) were seeded on BD Phenol Red-Free Matrigel matrix (100µL per
well; BD Biosciences, Bedford, MA) into a 96-well plate. After 1h incubation at 37°C, growth
medium was replaced with serum-free medium containing appropriate amounts of glucose (9).
Recovery experiments were performed by incubating treated cells with VEGF (20ng/ml).
Pictures were taken at 40X magnification using a Nikon Diaphot microscope (Nikon Canada,
Mississauga, ON) with PixeLINK camera (PixeLINK, Ottawa, ON). Images were captured
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from at least two field views/plate. Branch points were counted for each treatment and plotted
graphically.

2.2.9 Cell proliferation assay
Cell proliferation was analyzed colorimetrically by quantifying cleavage of WST-1 (Roche,
USA) by mitochondrial enzymes. Transfected HRECs were seeded at density of 2x104
cells/well in 96-well plates and cultured overnight. Cells were serum starved and treated with
various glucose levels for 48h. At the end of the timepoint, 20µl of WST-1 was added to each
well and incubated for 1h at 37 °C. Absorbance was measured at 490nm (39).

2.2.10 Fluorescence in situ hybridization
Cells were seeded at 75% confluency in 12-well plates and treated with various glucose levels
for 48h. FISH was performed according to the manufacturer’s protocol (biosearchtech.com/
stellaris protocols) (40). The probes were custom designed using the Stellaris FISH probe
designer and tagged with Cal Fluor Red 610 Dye (Biosearch technologies, Petaluma,CA).
Following hybridization of probes, the cells were counter-stained with Hoechst and mounted
with Vectashield mounting medium (Vector Labs, Burligame, CA). Positive stains were
detected with a fluorescent microscope (Olympus BX51; Olympus, Richmond Hill, ON,
Canada) and analyzed with ImageJ software.

2.2.11 RIP
RNA Immunoprecipitation (RIP) assay was conducted using Magna RIP RNA-Binding Protein
Immunoprecipitation Kit (Millipore, USA) following the manufacturer’s instruction (41). AntiEZH2 or anti-p300/CBP antibodies and IgG (control) were used for RIP (Millipore, USA). Coprecipitated RNAs were detected with real time RT-PCR.
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2.2.12 Immunohistochemistry
Mouse retinal sections were immunocytochemically stained for IgG using anti-mouse IgG
antibody (MP Biomedicals, OH,USA,) as previously described (42). The stains were arbitrarily
scored (0-3) in a masked fashion.

2.2.13 Statistical analysis
Data are expressed as mean ± SEM. To determine statistical significance, one-way ANOVA
followed by Tukey’s post-hoc test was performed as appropriate, using fixed-level testing with
level of significance set at 5%. GraphPad Prism 5 (GraphPad, San Diego, CA, USA) software
was used for statistical analysis.

2.3 Results
2.3.1 Glucose regulates ANRIL expression
Primary aim of this study was to identify the roles of glucose-induced alterations in lncRNA, to
mediate gene transcription in the pathogenesis of diabetic retinopathy. As endothelial cells are
primary targets of glucose-induced damage, we have used these cells to perform our in vitro
studies. VEGF is reported here as a downstream molecule, that is regulated by ANRIL. Hence,
HRECs were used to investigate alterations in ANRIL expression and its effect on VEGF
expression and function. HRECs were exposed to 25mM D-glucose (HG) environments for
various time points, using 5mM D-glucose (NG) glucose levels as controls. We observed HG
induced elevation in VEGF expression in a time dependent manner, with highest expression at
48h (data not shown). Hence for subsequent expression analysis 48h glucose incubation was
used. Microarray analysis conducted on HRECs post 48h HG incubation showed a 2.5fold
elevation in ANRIL (Fig 2.1A). The results were validated by real time RT-PCR (Fig 2.1B). A
significant, (≈1.8 fold) increase was seen with HG. Such relatively smaller increase may
possibly be explained by relatively small sample size. However, no significant ANRIL
alteration was seen following 25mM L-glucose (osmotic control) incubation (Fig 2.1B). We
performed RNA-FISH for ANRIL to examine its cellular distribution and to detect its
subcellular localization. We used custom designed RNA FISH probes consisting of 34
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complementary oligonucleotides, each 20 bases long and labeled with 3’end flurophore tag.
This approach has been shown to be highly specific for RNA detection (43). Glucose induced
upregulation of ANRIL expression was confirmed by this technique. No change in subcellular
distribution was noted following incubation with HG (Fig 2.1C and D). Interestingly, the cells
showed both cytoplasmic and nuclear distribution of ANRIL, although predominately localized
in an around the cytoplasmic side of the nuclear envelope (Fig 2.1C).

This image cannot currently be displayed.

Figure 2.1: Alteration of lncRNA ANRIL in HG (25 mM) versus control (NG; 5 mM). (A)
Volcano plot of differentially expressed lncRNAs in NG versus HG in HRECs. Vertical lines
correspond to 1.2-fold changes up and down, respectively, and the horizontal line represents a P
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value of 0.05. Red points indicate differentially expressed genes with statistical significance.
Arrow represents location of ANRIL. (B) Array data were validated by real-time RT-PCR
analysis of ANRIL, which confirmed its increased expression on exposure to HG (48 hours).
No alterations were seen following incubation with 25 mM L-glucose (osmotic control, Osm).
(RNA expressions are presented as a ratio of b-actin, normalized to NG.) (C) Fluorescence in
situ hybridization using probes against human ANRIL showed increased expression (nuclear
and perinuclear cytoplasmic) in HRECs exposed to HG versus NG (48 hours). (D) Quantitative
data following analysis using ImageJ confirmed glucose-induced ANRIL upregulation (MFI,
mean fluorescence intensity). Images quantified by ImageJ (*P < 0.05 versus NG. n=4 or
more/group).

2.3.2 ANRIL regulates glucose-induced expression and function of VEGF
We then proceeded to investigate mechanisms and significance of glucose-induced ANRIL
upregulation. ANRIL has been shown to interact with PRC2 complex, that regulates VEGF
expression (9,31). The role of ANRIL in VEGF regulation was explored by knocking down
ANRIL levels using siRNAs in HRECs. We used two siRNAs. As both gave similar results,
data from one are shown. VEGF upregulations at mRNA and protein levels are characteristic of
exposure of ECs to high levels of glucose. Such upregulations were prevented following
ANRIL siRNA transfection, showing a direct regulatory relationship (Fig 2.2A and B). As a
functional parameter, we examined VEGF-mediated angiogenesis using tube formation assays
on HRECs. Glucose-induced increased tube formation was prevented by ANRIL silencing. In
addition, such reduction in siANRIL transfected cells were rescued on further incubation with
VEGF (Fig 2.2C and D). WST-1 assay further revealed that cell proliferation was inhibited in
siANRIL transfected cells compared to scrambled controls. Meanwhile, rescue experiments
showed that VEGF incubation increased the cell proliferative ability in ANRIL transfected cells
both in low and high glucose (Fig 2.2E).
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Figure 2.2: ANRIL regulates glucose-induced VEGF expression in HRECs (48 hours).
Transfection of HRECs with ANRIL siRNA reduced (A) HG (25mM glucose)-induced
upregulation of VEGF mRNA and (B) protein expression compared with scrambled siRNA
(scr). Endothelial tube formation assay shows (C) representative micrograph and (D)
quantification using branch point assay. High glucose–induced increased endothelial tube
formation was prevented by ANRIL siRNA, which was subsequently rescued by incubation
with VEGF. (E) In parallel, ANRIL siRNA reduced endothelial cell proliferation (WST-1
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assay), which was also reversed following VEGF incubation (NG.5 mM glucose). Messenger
RNA expressions are presented as a ratio of b-actin, normalized to NG. Protein levels are
normalized to NG. *,#P < 0.05 versus scrNG or scrHG, n=4 or more per group).

2.3.3 Diabetes-induced retinal VEGF upregulation and function are
prevented in the ANRILKO mice
With goals to translate our findings and establish the observation in diabetic conditions, we
employed ANRILKO mouse models. Due to uncharacterized ANRIL mouse RNA sequence, as
per standard practice, its expression in mice was measured using p15, as a surrogate marker for
ANRIL (Fig 2.3B) (38). The wild type and KO animals following STZ-induction were
monitored for a period of 2 months. Diabetic mice demonstrated hyperglycemia (Fig 2.3A),
polyuria, glycosuria and reduced body weight gain, distinctive of poorly controlled diabetes
(data not shown). ANRILKO had no effect on these parameters except for urine volume. Urine
findings are further being investigated and will be reported separately.
We examined retinal tissues from the diabetic and control animals and analyzed for ANRIL and
VEGF expression. ANRIL upregulation was observed in the retina of wild type diabetic
animals. In addition, VEGF mRNA and protein levels were elevated in diabetes. All such
changes were prevented in the ANRILKO diabetic animals (Fig 2.3C and D).
We stained the retinal tissues for IgG. Extravasated IgG is a marker for increased permeability,
a functional effect of VEGF (45). Diabetes caused increased retinal microvascular permeability
in wild type diabetic animals (score 3, compared to score 0 in wild type controls), which was
prevented in the retina of diabetic ANRILKO mice (score1) (Fig 2.3E). These observations
suggested that ANRIL regulates VEGF expression and its functional consequences in diabetic
retinopathy.
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Figure 2.3: ANRIL regulates retinal VEGF in diabetic mice. (A) Diabetic wild-type (WT-D)
mice and diabetic ANRILKO (KO-D) mice showed hypergylcemia and reduced body weight
(data not shown). (B) Basal and diabetes-induced ANRIL RNA expression in the retina,
measured by p15, its surrogate marker, was significantly reduced in the control ANRILKO mice
(KO-C) mice and KO-D mice. Diabetes-induced elevation of VEGF (C) mRNA and (D) protein
expression levels were also prevented in retina of KO-C and KO-D animals. (E)
Immunohistochemical stain on mouse retina using anti-IgG antibody showing increased
extravascular diffuse stain, indicating increased extravasation (score 3) in the WT-D compared
with wildtype controls (WT-C) (score 0). Such changes were prevented in KO-D (score 1).
Messenger RNA expressions are presented as a ratio of b-actin, normalized to WT-C. Protein
levels are normalized to WT-C. *,#P < 0.05 versus WT-C or WT-D, n . 8.
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2.3.4 ANRIL causes VEGF upregulation through PRC complex
We carried out additional in vitro experiments to gain mechanistic insight of ANRIL’s actions
as seen above. We have previously shown that glucose-induced miR200b-mediated VEGF
upregulation works through PRC2 complex (9). PRC2 is part of transcriptional-repressive
complexes PRCs (PRC1, PRC2) and consists of many subunits (eg. EZH2, EED, SUZ12 and
RpAp46/48) (46). These complexes are critical in the epigenetic regulation of the CDKN2A/B
locus (31,47). Hence, we examined whether ANRIL has any regulatory relationship with PRC2
complex in diabetic retinopathy. We measured expression of EZH2, which was upregulated in
HRECs on exposure to HG, and in the retina of diabetic animals (Fig 2.4A and D) (9).
ANRILKO resulted in a significant downregulation of EZH2 levels (Fig 2.4A and D). EED
expression levels were similarly altered, whereas SUZ12 levels remained unaffected (Fig
2.4B,C,E,F).
To establish a cause effect relationship, we used DZNEP, a global methylase blocker, to inhibit
PRC2 activity. All components of the PRC2 complex were suppressed by this methylase
blocker (Fig 2.4G-I) (48). This blockade resulted in reduction of mRNA expression levels for
both VEGF and ANRIL (Fig 2.4J and K), suggesting regulatory effect of PRC2 on ANRIL and
VEGF.
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Figure 2.4: ANRIL–PRC2 complex interaction. Transfection of HRECs (48 hours) with
siANRIL reduced HG (25 mM glucose)-induced (A, B) upregulation of EZH2 and EED
mRNA, whereas SuZ12 mRNA (C) remained unaltered. (D–F) Diabetes-induced increased
retinal mRNA expression of EZH2 and EED was similarly reduced in ANRILKO mice
[controls (KO-C) and diabetic (KO-D)], whereas SUZ12 levels were unaffected. (G) EZH2
mRNA overexpression in HG were blocked by the global histone methylation inhibitor
DZNEP. (H, I) 3-Deazaneplanocin A also reduced upregulation of EED and SUZ12. (J, K) 3Deazaneplanocin A also reduced glucose-induced ANRIL and VEGF mRNA upregulation
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(WT-C, WT-D, NG [5 mM glucose]). Messenger RNA expressions are presented as a ratio of
b-actin, normalized to NG/WT-C. *P < 0.05 versus scrNG/WT-C, #P < 0.05 versus scrHG or
WT-D, and n. 8 or more per group.

2.3.5 ANRIL acts through p300 and miR200b
We have previously shown that VEGF is also regulated by miR200b through p300 (8). We
explored the relationship of ANRIL in this context. Interestingly, we found that reduction in
ANRIL expression using siRNA, resulted in correction of glucose-induced upregulation of p300
(Fig 2.5A). In retinal tissues of control and diabetic animals, ANRILKO also significantly
reduced expression of p300 (Fig 2.5B). These findings indicate that ANRIL regulates glucosemediated increase in p300 in diabetic retinopathy (8,34). To further examine possible feedback
regulation of ANRIL by p300, we silenced p300 in HRECs (such silencing led to ≈75%
reduction in p300 mRNA expression) and observed no effect of this alteration on ANRIL
expression (Fig 2.5C). On the other hand, ANRIL silencing also reduced glucose-induced
miR200b downregulation (Fig 2.5D).
We further established possible interaction of ANRIL with EZH2 component of PRC2 and
p300 thorough RNA-IP (RIP) assay in HRECs. ANRIL expression levels were determined by
real time RT-PCR on the samples immunoprecipitated using specific antibodies to EZH2 and
p300 (Fig 2.5E and F). Binding of ANRIL to p300 was significantly elevated when exposed to
high glucose levels. There was also increase in EZH2 binding to ANRIL under HG. This data
strongly indicates that ANRIL directly binds to both p300 and EZH2 when exposed to high
levels of glucose.
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Figure 2.5: Interaction of ANRIL with the histone acetylator p300 and miR200b.Transfection of
HRECs (48 hours) with siANRIL reduced HG (25 mM glucose)-induced (A) upregulation of
p300 and (D) downregulation of miR200b versus control (NG; 5 mM glucose). (B) Diabetesinduced elevated p300 mRNA expressions were prevented in the retinal tissues of diabetic
ANRILKO mice (KO-D; n=8/group). (C) However, silencing of p300 by siRNA did not alter
ANRIL mRNA expression in HRECs. (E, F) RNA-IP with anti-EZH2 and anti-p300 performed
in HRECs showed glucose-induced increased binding of ANRIL with the molecules (anti-IgG
as negative control). (G) A schematic outline of the mechanism related to ANRIL upregulation
and its interactions with p300, miR200b and PRC2 complex in mediating VEGF upregulation in
diabetic retinopathy. In this process ANRIL binds with EZH2 and p300. It further regulates
miR200b expression. A combination of all these mechanisms ultimately cause glucose-induced
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VEGF upregulation. (WT-C= wildtype controls, WT-D=wildtype diabetic, KOC=ANRILKO
controls, mRNA expressions are presented as a ratio of b-actin, normalized to NG/WT-C. *P <
0.05 versus WT-C or scrNG or anti-p300NG, #P < 0.05 versus WT-D or scrHG or antiEZH2HG or anti-p300HG. N= 3 or more per group of cells.

2.4 Discussion
In this study, we have demonstrated that lncRNA ANRIL is upregulated in response to high
levels of glucose. ANRIL regulates glucose-mediated upregulation of VEGF through its
interaction with p300 and PRC2 components in glucose-exposed ECs and in the retinal tissue of
diabetic animals.
Present-day treatments for proliferative diabetic retinopathy revolve around destructive
treatments of laser photocoagulation, vitreo-retinal surgery and blocking VEGF signaling (49).
Targeting the transcriptional process may constitute a novel approach. Majority of the human
genome sequences studied till date are protein-coding which comprises only 1.5% of the entire
genome (50). Recently, focus has been drawn onto the remaining non-coding area of the
genome and its importance in normal development and relevance in diseases (51). ncRNAs
generated from non-coding areas, when functional, exerts regulatory activities independent of
the protein-encoding route. Hence, they constitute potential drug targets (52). Here we focus on
a specific lncRNA in diabetic retinopathy.
The various roles of lncRNAs include modulation of alternate splicing, chromatin remodeling,
cis/trans-acting regulators of gene expression and RNA metabolism (53-56). Dysregulation of
target genes leads to abnormal lncRNA expression responsible for cellular defects and disease
progression including carcinogenesis and neurodegeneration (51,57). Our study demonstrates an
important and novel, regulatory role of lncRNA ANRIL in VEGF regulation in diabetic
retinopathy.
Originally identified from familial melanoma patients, ANRIL is a potential target for
cardiovascular diseases (24). It has been known to be associated with diabetes, open angle
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glaucoma and various cancers (58). We found that ANRIL binds to both p300 and EZH2 of the
PRC2 complex to regulate VEGF expression, characteristic of retinal degeneration in diabetes.
Microarray analysis followed by cellular and tissue data confirmed the glucose-mediated
upregulation of ANRIL. Interestingly, ANRIL showed perinuclear localization in HRECs. In
contrast, ANRIL has been previously reported to show nuclear expression in gastric cancer (33).
However, lncRNAs have been observed to show cell-to-cell variability in expression patterns
(59).
Histone methylation and acetylation are well characterized epigenetic marks implicated in
diabetic complications (60,61). Histone methylation involves transfer of methyl groups to
amino acid residues by histone methyltransferases such as EZH2 (PRC2 complex) (62). In some
tumors, increased EZH2 promotes VEGF stimulation and subsequent angiogenesis (63). In our
experiments, in ANRIL silenced HRECs and in ANRILKO mice, reduced levels of VEGF were
accompanied by EZH2 reduction. EZH2 blockade resulted in reduction in ANRIL and VEGF
RNA expression, showing a cause-effect relationship. We have previously demonstrated
interaction of miR200b with SUZ12 of PRC2 complex in the regulation of VEGF (9). The
upregulation of miR200b in siANRIL transfected HRECs suggests another interaction of
ANRIL with mir200b in the regulation of VEGF.
Diabetic ANRILKO animals and HRECs in HG following ANRIL siRNA transfection showed
reduction in p300 mRNA expression. We have previously demonstrated that p300 is
upregulated in diabetes and it controls multiple gene expressions (64). We have also previously
shown miR200b-dependent increased production of p300 in diabetic retinopathy (8) and
glucose-induced upregulation of VEGF was prevented by p300siRNA (34). Retinal tissues from
ANRILKO diabetic animals showed downregulated expression of p300 along with the lowering
of VEGF. Furthermore, RNA-IP assay revealed significantly stronger binding of ANRIL with
p300 after exposure to HG. Hence, another route of ANRIL regulating VEGF maybe mediated
through its effect on the transcriptional regulator, p300. To the best of our knowledge this is
also the first direct demonstration of ANRIL mediated p300 regulation in diabetes. A schematic
outline of the regulatory process as observed in this study is outline in Fig 2.5G.
Numerous lncRNAs associate with and possibly target histone-modifying activities (59).
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LncRNA scaffolds are now known to organize the concerted activities of chromatin-modifying
complexes spatially and temporally (65,66). For example, HOTAIR associates with PRC2 and
Lys-specific demethylase 1(LSD1) (67). PRC2 and LSD1 are responsible for the deposition of
the repressive histone marks and removal of active histone marks, respectively. Recently, in
other systems overexpression of ANRIL is known to change p300, mediating epigenetic
modifications (32). Hence a pattern of combined interaction of ANRIL with PRC2 and p300
might be an important mechanism in its regulation of VEGF in diabetic retinopathy. Hence
ANRIL-mediated VEGF upregulation is not direct and is mediated by the aforesaid molecules.
However, it is possible that additional molecules, including other lncRNAs and other mediators
may potentially be involved in such regulations. Such pathways need additional investigations.

Although there are no previous reports on ANRIL alterations in diabetic retinopathy, recently
another lncRNA MIAT has been shown to be upregulated in diabetic retinopathy (68).
However, exact pathways for ANRIL upregulation in the genome are not clear. LncRNAs are
under the same regulatory process as that of coding genes (69). Hence, hyperglycemia induced
oxidative stress and subsequent alterations of transcriptional machinery may also potentially
regulate such process.
In summary, we have shown that in the retinal endothelial cells, glucose causes upregulation of
ANRIL. This upregulation is responsible for altered VEGF expression and function. We further
confirmed these novel findings in ANRILKO mice with STZ-induced diabetes. The regulatory
effect of ANRIL on VEGF was mediated by interactions of ANRIL with components of PRC2
complex and histone acetylator, p300. The current data from this study sheds light on a
potentially new, targeted method to prevent diabetic retinopathy using an RNA based approach.
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3 ANRIL regulates production of extracellular matrix proteins
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3.1 Introduction
Diabetes comprises of various metabolic conditions involving cell’s inability to transport
and utilize glucose. According to International Diabetes Federation Atlas, worldwide
diabetic population was 438 million in 2015 and predicts a rise to 642 million in 2040;
with majority of the new diabetic population emerging from Asia (31). As the number of
people with diabetes steadily rises, chronic diabetic complications remain the significant
cause of morbidity. At present, the treatment involves dietary modifications, exercise
and weight loss, oral medications and insulin. Recent years have seen important advances
in the field of pathogenesis in diabetes, affecting cardiovascular, renal and nervous
systems as well as vision and lower extremities (4).
Diabetic nephropathy (DN) continues to be leading cause of end-stage renal failure
requiring renal replacement therapy (27,62). Excess mortality is observed in people with
DN, with impaired glomerular filtration rate (eGFR) and/or albuminuria (1,29). For
unknown reasons, 20% to 40% of patients with diabetes develop DN associated with
micro or macro-albuminuria and subsequent renal failure (50). Furthermore, there is an
increased risk for the development of ventricular dysfunction leading to cardiac
hypertrophy and failure in diabetic patients, known as diabetic cardiomyopathy (DCM)
(11,46). Alterations in myocardial structure, calcium signaling and metabolism are
features that precede the above-mentioned changes (9).
Multiple mechanisms contribute to the initiation and progression of DN and DCM. These
include hyperglycemia induced hemodynamic changes such as activation of vasoactive
factors such as VEGF as well as genetic predisposition, setting the stage for injury and
organ failure (7). Overall effects of hyperglycemia lead to structural and functional
changes in the target organs. The renal tissues undergo alterations such as glomerular
basement membrane thickening, increased mesangial matrix synthesis and compromised
selective glomerular permeability; eventually leading to glomerulosclerosis and

83

interstitial fibrosis (26). The abnormal vessels formed due to enhanced VEGF signaling
are

associated

with

glomerular

hypertrophy,

increased

capillary

occlusions,

tubulointerstitial injury and urinary albumin excretion in the kidneys (38). In the heart,
diabetes increases fatty acid metabolism, and alters intracellular signaling leading to
impairment in excitation–contraction coupling and inefficient production of energy.
These changes are likely to augment development of left ventricular hypertrophy,
increased sensitivity to ischemic injury and likelihood of heart failure (37).
Interstitial fibrosis is a robust indicator of disease progression during diabetes (5). It
involves accumulation and deregulated remodeling of extracellular matrix (ECM)
proteins such as fibronectin (FN), novel chains of laminin and type IV collagen (Col1α4)
(20). The excess accumulation of ECM in the heart mirrors occurrences in the kidneys
and peritoneum during diabetes. Changes to cardiac tissues include myocardial stiffening
as a result of cross-linking and ECM deposition, hypertrophy and neuronal abnormalities
culminating in diastolic dysfunction (3). In kidneys, there is gradual scarring of
glomerulus (glomerulosclerosis) as a result of ECM accumulation in the mesangial
interstitial spaces (44). The continued augmented synthesis, deposition and reduced
degradation of these ECM proteins and their post-translational modifications contribute
to development of fibrosis (12,33).
Ethnicity and differences in inherited genetics has been proposed as response to the
damage in both kidneys and heart due to diabetes (34,60). The molecular basis
underlying these complications remains unknown (34). Recent evidence has suggested
important roles of epigenetics leading to DN and DCM. The epigenetic modifications
include DNA methylation at cytosine, posttranslational modifications (PTMs) of histones
like acetylation and methylation, and alterations of noncoding RNAs (ncRNAs) (43).
ncRNAs; such as microRNAs and long noncoding RNAs (lncRNAs) are important parts
of the epigenetic realm due to their ability to regulate gene expression at both
transcriptional and translational levels (54). The long transcripts of lncRNA (200-2000nt)
lack protein-coding capability (13). They can regulate local and distal genes by various
mechanisms and play key roles in diverse biological processes (59).
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lncRNA ANRIL consists of 19 exons, spanning 126.3kb, and is situated in
p15/CDKN2B-p16/CDKN2A-p14/ARF (INK4b-ARF-INK4a) gene cluster, in the
antisense direction (2). We have recently reported that ANRIL is upregulated in human
retinal endothelial cells (HRECs) and retinal tissues of diabetic mice. Upregulated
ANRIL regulates VEGF through interaction with EZH2 of polycomb repressive complex
2 (PRC2) and histone acetylator, p300 (53). ANRIL is known to function as a recruiter of
PRC complexes to facilitate altering of chromatin structure and set the stage for gene
regulation (61). Recent “allele-specific” functional genomic studies showed preferential
binding of p300 led to increased interaction of chromatin with ANRIL promoters, thereby
activating transcription of the lncRNA (39). Others and we have described the regulatory
role of ANRIL on the expression of p300, a well-known regulator of FN in diabetic
complications (15, 24, 53). ANRIL locus is a hotspot for numerous disease-associated
polymorphisms and DNA alterations where they regulate genomic neighbors in both cis
and trans (2). It has been steadily associated with cardiovascular diseases as well as
cancer, diabetes, glaucoma and other conditions (17).
Here we investigated the specific role of ANRIL in regulating the production of ECM
protein and VEGF in DN. We further expanded this study to examine whether similar
changes occur in DCM. The study was focused on investigating alterations in ANRIL
expression in the kidneys and heart of streptozotocin (STZ)-induced diabetic mice. To
examine specific role of ANRIL, we used a unique tool, i.e ANRIL-/- mice with STZinduced diabetes. Subsequently we determined if the alterations resulted in pathologically
significant modifications to the structure and function of these organs. We further
investigated if ANRIL’s regulation of ECM proteins and VEGF is modeled through p300
or PRC2- mediated pathway in DN and DCM.
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3.2 Materials and Methodology
3.2.1 Animals
All animals were cared for according to the guiding principles in the care and use of
animals. The experiments were approved by Western University and Animal Care and
Veterinary Services. All experiments conform to the guide for care and use of laboratory
animals published by the NIH (NIH publication no. 85-23, revised in 1996).
ANRIL knockout (129S6/SvEvTac-Del(4C4-C5)1Lap/Mmcd) mice, acquired from
Mutant Mouse Resource & Research Centre (MMRC, Davis, CA). ANRIL had been
identified to be located within the p15/CDKN2B-p16/CDKN2A-p14/ARF gene cluster
(INK4 locus) and occurs anti-sense to these genes in the cluster. As the mouse RNA for
ANRIL hasn’t been characterized yet, ANRILKO mouse model was created on a
129S6/SvEv background where 70kb region on Chr 4 of the mouse gene aligning to
human 58-kb non-coding CAD risk interval was removed by targeted deletion. The
deletion was confirmed as the mice had significantly reduced expression levels of the
neighboring genes CDKN2A and CDKN2B (located on the INK locus along with
ANRIL), whereas there was no substantial expression change of other neighboring genes,
Mtap and Dmrta1 (located outside of the INK locus) (57). We have also confirmed
ANRILKO by measuring mRNA expression of CDKN2B (p15) in the mice tissues (Fig
3.1 A).
Diabetes was induced with STZ (five doses) intraperitoneally (50mg/kg in citrate buffer,
pH5.6) on consecutive days (22). Age and sex-matched littermate controls received equal
volume of citrate buffer. Blood glucose (>20mmol/L) measured from tail vein bi-weekly
over the course of the study using a glucometer, confirmed diabetes. Animals were
monitored for variations in body weight and blood glucose. Mice were sacrificed after 8
weeks and tissues were collected.
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3.2.2 Echocardiography
Echocardiography was used to measure left ventricular hypertrophy (LVH), a marker for
heart failure and myocardial infraction. Diabetic and control animals (wild types and
ANRILKO) were lightly anesthetized (1.5% inhaled isoflurane) and subjected to
echocardiography on a warm handling platform. A 40-MHz linear array transducer (MS550D) and Vevo 2100 preclinical ultrasound system (VisualSonics, ON, Canada) were
used for the experiment. Left ventricular fractional shortening (FS) was used as cardiac
contractile function index. Pulse waved color flow-guided Doppler recordings of
maximal early (E) and late (A) diastolic transmittal flow velocities and Doppler tissue
imaging recordings of peak E’ velocity and peak A’ velocity was collected. Mitral inflow
patterns (E/A ratio) and mitral annulus velocities (E’/A’) were used to assess diastolic
dysfunction as reported previously (22).

3.2.3 RNA analysis
TRIzol reagent (Invitrogen, Canada) was used to extract total RNA as previously
described (23). cDNA for PCR was synthesized with high-capacity cDNA reversetranscription kit (Applied Biosystems, Burlington, ON, Canada). mRNA expression was
detected through real time RT-PCR using LightCycler (Roche Diagnostics).
Housekeeping gene β-actin was used to normalize the data.

3.2.4 ELISA
Total protein was extracted from kidney and heart tissues and concentrations measured
by bicinchoninic acid (BCA) method. ELISA was performed to measure expression of
FN and Col1α4 protein in mouse kidney tissues using a commercially available kit
(Bosterbio, CA, USA) according to the manufacturer’s instructions (15).

3.2.5 Luminex Assay
Multiplex luminex assay for angiogenesis was used to measure VEGF and hepatocyte
growth factor (HGF) protein concentration in tissues extracted from heart and kidney of
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diabetic and control mice. Tissues were extracted with RiPA buffer followed by
precipitation with 80% ice cold acetone (8). Acetone precipitation was performed to
ensure samples were devoid of possible colour from the extracted tissue that might
interfere with the assay. Protein concentration of tissue lysate was measure by BCA
assay. The samples (<500 mg/ml) were assessed using Luminex technology with
Milliplex Mouse MAP Angiogenesis kit (Millipore, MA,USA) containing multiplex
magnetic bead-based antibody detection kit according to manufacturer’s protocol (55).

3.2.6 Urine albumin assay
24 hr urine was collected from the animals by placing them in metabolic cages before
sacrifice with care so that feaces did not contaminate the urine samples. Measurement of
urinary albumin and creatinine was performed by ELISA (Albuwell M; Exocell,
Philadelphia, PA, USA). All procedures were performed using manufacture’s protocol
and the data was used to calculate urinary albumin:creatinine ratio (UACR) (16).

3.2.7 Histology and Immunohistochemistry
Renal cross-sections were fixed and embedded in paraffin and sectioned at 5µm thickness
on positively charged slides. The sections were de-paraffinized in xylene and stained with
periodic acid-Schiff (PAS) for assessment of glomerulosclerosis and mesangial
expansion and Masson’s trichome-stain for evaluation of interstitial expansion as
described elsewhere (48). The stains were arbitrarily scored (0-3) in a masked fashion
(42).
For immunohistochemical staining, the de-paraffinized kidney and heart sections were
antigen-retrieved in citrate buffer and incubated with primary antibodies overnight at
4°C. The primary antibodies (Abcam, MA, USA) used were rabbit anti-mouse FN and
Col1α4 (1:100). The slides were incubated in ImmPRESSTM (Peroxidase) anti-rabbit IgG
Reagent kit (Vector Lab, CA,USA) for 30 mins, mounted and viewed under microscope
(40).
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3.2.8 Statistical analysis
Statistical significance was determined by Student’s t-test or one-way ANOVA followed
by post-hoc test when appropriate. Data are expressed as mean ± SEM. A p value of 0.05
or less was considered to be significant and results are expressed as average of n = 5-8
animals per group. GraphPad Prism 5 (GraphPad, CA, USA) software was used for
statistical analysis.

3.3 Results
3.3.1 ANRIL expression is elevated in kidneys of diabetic animals
We observed a protective effect of ANRIL nullification in HRECs and retina of diabetic
mice in our previous study (53). Similar phenomena were investigated in diabetic kidneys
in this research. Since ANRIL mouse RNA sequence remains uncharacterized, as per
standard practice, its expression in mice was measured using p15, as a surrogate marker
for ANRIL (Fig 3.1A) (57). Following STZ-induction, wildtype and ANRILKO animals
were monitored for a period of 2 months. Hyperglycemia was evident in the diabetic
animals (Fig 3.1B), along with polyuria, glycosuria and reduced body weight (Fig 3.1C),
distinctive of poorly controlled diabetes. Interestingly, although ANRILKO had no effect
on the above parameters, the urine volume in the diabetic ANRILKO animals were
significantly less than in wildtype diabetics (Fig 3.2A).
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Figure 3.1: ANRIL expression in diabetes. (A)ANRIL mRNA expressions were increased
in the kidneys of wild-type diabetic mice (WT-D) compared with the wild-type
nondiabetic controls (WT-C). Both basal and diabetes-induced upregulated ANRIL
expression were reduced in ANRIL-knockout (ANRILKO) controls (KO-C) and
ANRILKO diabetics (KOD), respectively [ANRIL expression was measured by p15, its
surrogate marker]. WT-D mice and KO-D animals showed hyperglycemia (B) and
reduced body weight (C) gain following 2 months of diabetes compared with controls
(WT-C and KO-C). (*P 0.05 vs. WT-C, #P 0.05 vs.WT-D; n 8/group).
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Figure 3.2: ANRIL regulates structural and functional changes in the kidneys of diabetic
animals. Diabetes-induced elevated urine excretion (polyuria; A) and increased renal
albumin/creatinine ratio (B) were prevented in the diabetic animals lacking ANRIL (KOD). (C) Kidneys of wild-type diabetic (WT-D; score 3) mice showed mesangial
expansion (periodic acid-Schiff stain; arrows show pink extracellular matrix protein
deposition) compared with wild-type controls (WT-C; score 0) and ANRILKO controls
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(KO-C; score 0). Such changes were prevented in the diabetic animals lacking ANRIL
(KO-D; score 1). Immunohistochemical staining of kidney sections (D) for fibronectin
(FN) showed significantly elevated positive stain (arrows) in the WT-D animals, which
were prevented in KO-D mice. (E) Kidneys of wildtype diabetic (WT-D; score 0) and
diabetic animals lacking ANRIL (KO-D) showed no significant increase in tubuleinterstitial scarring (dark staining of Trichome stain) compared with wild-type controls
(WT-C; score 0). *P 0.05 vs. WT-C, #P 0.05 vs. WT-D. Bar 10µm, same magnification
for all micrographs; n 8/group.

3.3.2 ANRIL regulates renal structure and function in the diabetic
mice
Kidney dysfunction generally reflects pathological changes in the kidneys in diabetes.
We estimated urine volume and albumin-creatinine levels, which showed renal protection
in the ANRILKO, as this ratio is characteristically elevated in wildtype diabetics (Fig
3.2B). We further stained the kidney sections with PAS stain. The stains showed
increased mesangial matrix protein deposition in the wildtype diabetics. The increased
mesangial matrix depositions were prevented in diabetic ANRILKO animals (Fig 3.2C).
Trichome staining of the tissues did not show any significant increase in tubuleinterstitial scarring in the diabetic animals as these changes could be more prevalent at
later time points (Fig 3.2E).

3.3.3 ECM proteins are regulated by ANRIL in diabetic animals
The finding of reduced urine volume and Alb/Cre ratio directed us to think of a
protection in the ANRILKO animals against hyperglycemic insults. Increased production,
deposition and reduced breakdown of ECM proteins are key features of DN. We
measured the FN and Col1α4 levels to find whether such protection was due to reduced
deposition of these proteins. Immunohistochemical stains showed significantly elevated
FN levels in the wildtype diabetic groups compared to non-diabetics and diabetic
ANRILKO animals (Fig 3.2D). Similarly, increased levels of mRNA and protein
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expression of ECM proteins, FN and Col1α4, observed in wildtype diabetic animals were
prevented in the ANRILKO diabetic animals (Fig 3.3A-D).

3.3.4 ANRIL regulates VEGF production in the kidneys in diabetes
ANRIL regulates vasoactive factors such as VEGF in the retina during diabetes (45). We
further explored the possibility of such regulation in the kidneys. The mRNA and protein
levels of VEGF were increased in diabetic wildtypes compared to controls. mRNA
alterations were prevented in ANILKO diabetic animals (Fig 3.3E and F). In contrast,
mRNA expression of hepatocyte growth factor (HGF) remained elevated in both
wildtype and ANRILKO diabetic animals (Fig 3.3G). This observation indicates
ANRIL’s role to be specifically acting through regulation of ECM proteins and VEGF.
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Figure 3.3: ANRIL regulates extracellular matrix (ECM) proteins and VEGF in kidneys
of diabetic animals. (A–D) Diabetes induced elevation of ECM proteins; FN mRNA (A),
FN protein (B), type IV collagen (Col14) mRNA (C), and Col14 protein (D) levels were
prevented in the kidneys of ANRILKO diabetic animals (KO-D). Increased expression of
VEGF at the mRNA (E) and protein (F) levels were significantly prevented in the KO-D
animals. G: the elevated mRNA levels of hepatocyte growth factor (HGF) in diabetes
remained unaffected in KO-D. WT-C, wild-type controls; WT-D, wild-type diabetics;
KO-C, ANRILKO control. *P 0.05 vs. WT-C, #P 0.05 vs. WT-D; n 8/group.
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3.3.5 ANRIL works in association with other epigenetic regulators
ANRIL works in concert with other epigenetic regulators, such as p300, a histone
acetylator and EZH2, histone methyltransferase component of PRC2 complex (53). As
expected, these components were increased in the kidneys of wildtype diabetic mice and
were corrected in the diabetic ANRILKO kidney tissues (Fig 3.4A and B). The other
components of PRC2, namely embryonic ectoderm development protein (EED) and
suppressor of zeste (SUZ12) were not altered in the ANRILKO mice compared to
wildtypes (Fig 3.4C and D).

Figure 3.4: ANRIL’s action is mediated by epigenetic mechanism. Diabetes-induced
increased renal mRNA expressions of p300 (A) and enhancer of zeste 2 (EZH2; B) were
prevented in diabetic ANRILKO animals (KO-D), whereas embryonic ectoderm
development protein (EED; C) and suppressor of zeste (SUZ12; D) mRNA levels were
unaffected. WT-C, wild-type controls; WT-D, wild-type diabetics; KO-C, ANRILKO
controls. *P 0.05 vs. WT-C, #P 0.05 vs. WT-D; n 8/group.

95

3.3.6 ANRIL-mediated ECM and VEGF regulation in diabetic hearts
We extended our study to examine if other organs, namely cardiac tissue, were similarly
affected. Heart tissue was analyzed to elucidate possible regulatory role of ANRIL in
development of DCM and subsequent structural alterations. We observed similar
alterations in expression levels of FN, Col1α4 and VEGF as seen in kidneys (Fig 3.5AD). Immunohistochemical analysis showed elevated FN and Col1α4 protein expression in
wildtype diabetic groups compared to control groups and diabetic ANRILKO animals
(Fig 3.6A and B). However, trichome stain failed to show any obvious scarring (data not
shown). We also performed echocardiographic examination on the live animals to
examine any functional changes in the cardiac functional changes among various groups
(Fig 3.6C-E). This lack of functional changes in the diabetic animals may, at least in part
be explained by lack of significant scarring in this species.
Our analysis of mRNA expression levels of p300 and EZH2 of the PRC2
complex suggested that ANRIL may regulate ECM and vasoactive proteins in heart by
similar epigenetic mediators (Fig 3.7A and B). The other two components of PRC2
complex; EED and SUZ12 remained unaffected by altered ANRIL levels (Fig 3. 7C and
D).
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Figure 3.5: ANRIL regulates ECM proteins and VEGF levels in cardiac tissues of
diabetic mice. Diabetes-induced elevation of FN (A), Col14 (B), and VEGF (C) mRNA
levels as well as VEGF protein expressions (D) was prevented in hearts of diabetic
ANRILKO animals (KO-D). WT-C, wild-type controls; WT-D, wild-type diabetics; KOC, ANRILKO controls. *P 0.05 vs. WT-C, #P 0.05 vs. WT-D; n 8/group.
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Figure 3.6: ANRIL regulates ECM protein expression in the cardiac tissues in diabetes.
Immunohistochemical staining of cardiac tissue sections for FN (A) and Col14 (B)
showed significantly elevated positive stain (arrows) in the wild-type diabetic (WT-D)
mice. Such elevations were prevented in the ANRILKO diabetic mice (KO-D).
Echocardiographic assay of mice showed no significant changes in fractional shortening
(FS; C), mitral inflow pattern (E/A ratio; D), or mitral annulus velocity (E=/A= ratio; E)
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levels between the groups. WT-C, wild-type controls; KO-C, ANRILKO controls. *P 0.05
vs. WT-C; #P 0.05 vs. WT-D. Bar 10µm (same magnification for all micrographs; n
8/group).

Figure 3.7: ANRIL’s action is mediated by epigenetic mechanisms. The elevated levels
of p300 (A) and EZH2 (B) observed in wildtype diabetic mice (WT-D) were prevented in
the diabetic ANRILKO animals (KO-D). However, increased EED (C) and SUZ12 (D)
levels in diabetes were unaffected in the KO-D animals. WT-C, wild-type controls; KOC, ANRILKO controls. *P 0.05 vs. WT-C, #P 0.05 vs. WT-D; n 8/group.

3.4 Discussion
In this research, we described the role of lncRNA ANRIL in regulating ECM proteins FN
and Col1α4 as well as angiogenic factor VEGF in DN and DCM. This regulation at least
in part is driven by ANRIL’s interaction with PRC2 complex proteins and p300 causes
functional changes in murine kidneys and heart. Polyuria and albuminuria levels
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characteristic of DN were prevented in the ANRILKO diabetic animals. Furthermore,
increased ECM protein deposition observed in glomeruli and in the heart of wildtype
diabetic mice were also absent in ANRILKO diabetics, evident through PAS stain.
Development and progression of DN, involves hyperglycemic insults on resident kidney
cells including endothelial cells (ECs) and podocytes (25). Similarly, ECs and
cardiomyocytes are affected in DCM (58). Multifactorial causes including genetic and
environmental factors can be ascribed to all chronic diabetic complications. Genetic
susceptibility in the development of these complications can be attributed to familial
aggregation, with a three-fold increase in risk for diabetic siblings of diabetic probands in
developing chronic complications such as DN (18). The emphasis on identifying
susceptible genes associated with chronic diabetes has led to widespread research
including candidate gene screening and genome-wide association studies (GWAS) (6,
45). Along with various factors like transcription factor binding affinity, disruption of
chromatin and post-translational modifications that are critical for modulation of gene
function by genetic variants; epigenetic control and regulation of genes provides an
additional layer of mechanism involved in the pathogenesis of diseases like chronic
diabetic complications (32).
Previously we had reported that the expression of ANRIL was upregulated in diabetic
retinopathy (53). ANRILKO led to the protection from upregulation of histone acetylator,
p300 as well as EZH2 component of the PRC2 complex characteristic of diabetic
complications. Similar to the retina, here we report that ANRIL controls the alteration
observed in the kidneys and heart in diabetes. This study showed that certain epigenetic
modulators histone acetylator, p300 and EZH2 of the PRC2 complex are also regulated
by ANRIL. Histone acetylation is an important post-transcriptional modification that
recruits protein complexes for the regulation of gene expression. Recent research has
highlighted the contribution of p300 in the development and persistence of diabetes and
its complications (36). We have also shown upregulation of histone methyltransferase
EZH2 of PRC2 components in diabetic complications (47,53). In our experiments, we
observed the decrease in expression of FN, Col1α4 and VEGF in the ANRILKO animals
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was accompanied by subsequent reduction in these epigenetic factors in the kidneys as
well as heart tissues. These findings indicate that ANRIL regulates these key molecules.
Our results further suggest that ANRIL’s interaction with the histone modifiers EZH2
and p300 may play a role in such process.
lncRNAs including ANRIL have been shown to have a strong association with ECM
protein-coding genes and are important regulators of fibrosis (30). Apart from binding of
transcription factors to the promoters of the protein-coding genes, transcriptional
activation or repression is linked to alteration in chromatin structure through histone
modifications and subsequent nucleosome re-modeling (56). Therefore, epigenetic
regulation of gene expression in the current context, involves a combined interaction
between lncRNAs, histone modifiers and other regulators. We and others have shown
that activation of histone acetylator, p300 is accompanied by increased expression of
vasoactive factors and ECM protein in the ECs and fibroblasts (15,28). Following
exposure to high glucose, there is enhanced binding of p300 to promoters of these genes
in ECs (15). However, unlike acetylation, histone methylation changes are often
continued down the cell lineage and thus, have received greater attention especially in
glycemic memory (21,41). In their study with cultured podocytes, Siddiqi and colleagues
found that deletion of histone methyltransferase, EZH2 with inhibitors or silencers
rendered the cells vulnerable to deleterious effects of high-glucose, leading to elevated
ROS levels and cell death (49). However, we have shown that ANRIL binds to both p300
and EZH2 and positively regulates their expression (53). Therefore, the protective effect
of ANRILKO seen in the kidneys and heart could be attributed to the downregulation of
p300 that might be directly regulating ECM protein and VEGF (15, 35). As for EZH2
downregulation, it might be leading to overexpression of other genes that might aid in the
protection imparted by ANRILKO in diabetic complications. The pathway of ANRIL’s
regulation of EZH2 needs to be explored further.
Hyperglycaemia is a well-known contributor for the damage to the ECs and subsequent
organ dysfunctions (14, 52). ANRIL expression has been reported in atheromatous
vessels, coronary smooth muscle cells and vascular ECs (10). Recently, Song and
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colleagues demonstrated that elevated ANRIL expression induced vascular cell apoptosis,
exacerbated EC inflammation and reduced artheroprotective effects, leading to EC
dysfunction in atherosclerosis. These features were reversed in the rat models treated
with ANRIL inhibitors (51). Similarly, our previous work showed a glucose-mediated
upregulation of ANRIL in HRECs and in retinal tissues, causing upregulation of key
proteins such as VEGF (53). The current study also shows similar regulation of VEGF
expression in DN and DCM.
We have demonstrated the regulatory interaction of lncRNA with histone acetylator and
the PRC2 complex protein. Interestingly lncRNAs’ effect may be mediated through
microRNAs (miRNAs). Recently, lncRNA TUG1 has been reported to decrease ECM
protein production by regulating miR-377 in DN (19). We have shown such interaction of
ANRIL with miR200b at the cellular level (53). Further studies are needed to expose
such possibilities with respect to DN and DCM. In addition, it is possible that other
miRNAs, lncRNAs and additional epigenetic mechanisms are also part of this orchestra,
which needs to be deciphered through additional well-designed experiments.
In summary, we have demonstrated that ANRIL may interact with epigenetic modifiers at
multiple levels in regulating the expression of ECM proteins and VEGF in the
pathogenesis of DN and DCM. While we acknowledge the role of other factors including
other lncRNAs in these regulatory mechanisms, targeted therapies directed at ANRIL
may have important implications in combatting chronic diabetic complications.

102

3.5 References
1. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de
Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc
Nephrol, 2013. 24: p. 302-308.
2. Aguilo F, Di Cecilia S, Walsh MJ. Long Non-coding RNA ANRIL and Polycomb
in Human Cancers and Cardiovascular Disease. Curr Top Microbiol Immunol,
2016. 394: p. 29-39.
3. Asbun J, Villarreal FJ. The Pathogenesis of Myocardial Fibrosis in the Setting of
Diabetic Cardiomyopathy. J Am Col Cardiol, 2006. 47: p. 693-700.
4. Bailes BK. Diabetes mellitus and its chronic complications. AORN J, 2002. 76: p.
266-276.
5. Barnes JL, Glass WF. Renal interstitial fibrosis: a critical evaluation of the origin
of myofibroblasts. Contrib Nephrol, 2011. 169: p. 73-93.
6. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, et
al. Methylation determines fibroblast activation and fibrogenesis in the kidney.
Nat Med, 2010. 16: p. 544-550.
7. Benjamin LE. Glucose, VEGF-A, and Diabetic Complications. Am J Pathol,
2001. 158: p. 1181-1184.
8. Botelho D, Wall MJ, Vieira DB, Fitzsimmons S, Liu F, Doucette A. Top-down
and Bottom-Up proteomics of SDS- containing solutions following mass-base
separation. Analytica Chimica Acta, 2013. 796: p. 48-54.
9. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr
Metab Disord, 2010. 11: p. 31-39.
10. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al; for the
PROCARDIS consortium. Susceptibility to coronary artery disease and diabetes
is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome
9p21. Hum Mol Genet, 2008. 17: p. 806-814.
11. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Mod Mech,
2009. 2: p. 454-466.
12. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney
Dis, 2000. 36: p. 449-467.
103

13. Cabili MN, Trapnell C, Goff L, Kozil M, Tazon-Vega B, Regev A, et al.
Integrative annotation of human large intergenic noncoding RNAs reveals global
properties and specific subclasses. Genes Dev, 2011. 2: p. 1915-1927.
14. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying
insulin resistance, diabetes, and cardiovascular disease? The common soil
hypothesis revisited. Arterioscler Thromb Vasc Biol, 2004. 24: p. 816-823.
15. Chen S, Feng B, George B, Chakrabari R, Chen M, Chakrabarti S.
Transcriptional coactivator p300 regulates glucose-induced gene expression in
endothelial cells. Am J Physiol Endocrinol Metab, 2010. 298: p. 127-137.
16. Chen S, Feng B, Thomas AA, Chakrabarti S. miR-146a regulates glucose induced
upregulation of inflammatory cytokines and extracellular matrix proteins in the
retina and kidney in diabetes. PLoS One, 2017. 2017: p. 1-17.
17. Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: molecular mechanisms
and implications in human health. Int J Mol Sci, 2013. 14: p. 1278-1292.
18. Doria A. Genetics of Diabetes Complications. Curr Diab Rep, 2010. 10: p. 467475.
19. Duan LJ, Ding M, Hou LJ, Cui YT, Li CJ, Yu DM. Long noncoding RNA TUG1
alleviates extracellular matrix accumulation via mediating microRNA-377
targeting of PPARγ in diabetic nephropathy. Biochem Biophys Res Commun,
2017. 483: p. 598-604.
20. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol, 2000. 15: p. 290301.
21. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient
high glucose causes persistent epigenetic changes and altered gene expression
during subsequent normoglycemia. J Exp Med, 2008. 205: p. 2409-2417.
22. Feng B, Cao Y, Chen S, Chu X, Chu Y, Chakrabarti S. miR-200b Mediates
Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy. Diabetes,
2016. 65: p. 1-11.
23. Feng B, Cao Y, Chen S, Ruiz M, Chakrabarti S. miRNA-1 regulates endothelin-1
in diabetes. Life Sci, 2014. 98: p. 18-23.

104

24. Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, et al. miR-146a–Mediated
Extracellular Matrix Protein Production in Chronic Diabetes Complications.
Diabetes, 2011. 60: p. 2975-2984.
25. Forbes JM and Cooper ME. Mechanisms of diabetic complications. Physiol Rev,
2013. 93: p. 137-188.
26. Gallagher H and Suckling RJ. Diabetic nephropathy: where are we on the journey
from pathophysiology to treatment? Diabetes, Obes and Metab, 2016. 18: p. 641647.
27. Ghaderian SB, Hayati F, Shayanpour S, Mousavi SSB. Diabetes and end-stage
renal disease; a review article on new concepts. J Renal Inj Prev, 2015. 4: p. 2833.
28. Ghosh AK, Varga J. The transcriptional coactivator and acetyltransferase p300
in fibroblast biology and fibrosis. J Cell Physiol, 2007. 213: 663-671.
29. Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, et al,
FinnDiane Study Group. The presence and severity of chronic kidney disease
predicts all-cause mortality in type 1 diabetes. Diabetes, 2009. 58: p. 1651-1658.
30. Huang ZP, Ding Y, Chen J, Wu G, Kataoka M, Hu Y, et al. Long non-coding
RNAs link extracellular matrix gene expression to ischemic cardiomyopathy.
Cardiovasc Res, 2016. 112: p. 543-554.
31. International

Diabetes

Foundation,

2015.

(Accessed

2017,

at

http://www.diabetesatlas.org/).
32. Knight JC. Approaches for establishing the function of regulatory genetic
variants involved in disease. Genome Med, 2014. 6: p. 1-15.
33. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol,
2011. 7: p. 684-696.
34. Lu Z, Liu N, Wang F. Epigenetic Regulations in Diabetic Nephropathy. J
Diabetes Res, 2017. 2017: p. 1-6.
35. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates
vascular endothelial growth factor-mediated alterations in diabetic retinopathy.
Diabetes, 2011. 60: p. 1314-1323.

105

36. Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling
events leading to inflammatory gene transcription under diabetic conditions. J
Biol Chem, 2004. 279: p. 18091-18097.
37. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology
and clinical features. Heart Fail Rev, 2013. 18: p. 149-166.
38. Nakagawa T, Kosugi T, Haneda M, Rivard CJ. Abnormal Angiogenesis in
Diabetic Nephropathy. Diabetes, 2009. 58: p. 1471-1478.
39. Nakaoka H, Gurumurthy A, Hayano T, Ahmadloo S, Omer WH, Yoshihara K, et
al. Allelic Imbalance in Regulation of ANRIL through Chromatin Interaction at
9p21 Endometriosis Risk Locus. PLOS Genet, 2016. 2016: p. 1-23.
40. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and Podoplanin, new
markers in the skull base chordoma vs chondrosarcoma differential: a tissue
microarray-based comparative analysis. Mod Pathol, 2008. 21: p. 1461-1469,
2008.
41. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, et al.
Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ
Res, 2012. 110: p. 1067-1076.
42. Pena AM, Chen S, Feng B, Cai L, Li X, Liang G, et al. Prevention of Diabetic
Nephropathy by Modified Acidic Fibroblast Growth Factor. Nephron, 2017. 137:
p. 1-16.
43. Portela A and Esteller M. Epigenetic modifications and human disease. Nature
Biotechnol, 2010. 28: p. 1057-1068.
44. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC III. Mechanisms of
Glomerulosclerosis in Diabetic Nephropathy. Diabetes, 2008. 57: p. 1439-1445.
45. Robertson KD. DNA methylation and human disease. Nature Rev, 2005. 6: p.
597-610.
46. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New
type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J
Cardiol, 1972. 30: p. 595-602.

106

47. Ruiz MA, Feng B, Chakrabarti S. Polycomb Repressive Complex 2 Regulates
MiR-200b in Retinal Endothelial Cells: Potential Relevance in Diabetic
Retinopathy. PLOS One, 2015. 10: p. 1-21.
48. Shao M, Lu X, Cong W, Xing X, Tan X, Li Y, et al. Multiple Low-Dose
Radiation Prevents Type 2 Diabetes-Induced Renal Damage through Attenuation
of Dyslipidemia and Insulin Resistance and Subsequent Renal Inflammation and
Oxidative Stress. PLOS One, 2015. 9: p. 1-17.
49. Siddiqi FS, Majumdar S, Thai K, Abdalla M, Hu P, Advani SL. The Histone
Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against
Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol,
2015. 27: p. 1-14.
50. Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic
mechanisms. Diab Res Clin Pract, 2008. 82: p. 75-79.
51. Song CL, Wang JP, Xue X, Liu N, Zhang XH, Zhao Z, et al. Effect of Circular
ANRIL on the Inflammatory Response of Vascular Endothelial Cells in a Rat
Model of Coronary Atherosclerosis. Cell Physiol Biochem, 2017. 42: p. 12021212.
52. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in
diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr
Metab Disord, 2010. 11: p. 61-74.
53. Thomas AA, Feng B, Chakrabarti S. ANRIL: A Regulator of VEGF in Diabetic
Retinopathy. Invest Ophthalmol Vis Sci, 2017. 58: p. 470-480.
54. Thomas MC. Epigenetic mechanisms in diabetic kidney disease. Curr Diab Rep,
2016. 16: p. 1-8.
55. Tong W, Ye F, He L, Cui L, Cui M, Hu Y, Li W, Jiang J, Zhang DY, Suo J.
Serum biomarker panels for diagnosis of gastric cancer. Onco Targets Ther,
2016. 9: p. 2455-2463.
56. Villeneuve LM and Natrajan R. The role of epigenetics in the pathology of
diabetic complications. Am J Physiol Renal Physiol, 2010. 299: p. F14-F25.

107

57. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, et al. Targeted
deletion of the 9p21 non-coding coronary artery disease risk interval in mice.
Nature, 2010. 464: p. 409-412.
58. Wan A, Rodrigues B. Endothelial cell–cardiomyocyte crosstalk in diabetic
cardiomyopathy. Cardiovasc Res, 2016. 111: p. 172-183.
59. Wapinski O and Chang HY. Long noncoding RNAs and human disease. Trends
Cell Biol, 2011. 21: p. 354-361.
60. Winham SJ, de Andrade M, Miller VM. Genetics of cardiovascular disease:
importance of sex and ethnicity. Atherosclerosis, 2015. 241: 219-228.
61. Yap KL, Li S, Munoz-Cabello A, Raguz S, Zeng L, Mujtaba S, et al. Molecular
Interplay of the Non-coding RNA ANRIL and Methylated Histone H3 Lysine 27 by
Polycomb CBX7 in Transcriptional Silencing of INK4a. Mol Cell, 2010. 38: p.
662-674.
62. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes
epidemic. Nature, 2001. 414: p. 782-787, 2001.

108

Chapter 4

4 LncRNA H19 reverses Endothelial-Mesenchymal Transition
in Diabetic Retinopathyc

1

c

Anu Alice Thomas1, Saumik Biswas1, John Gonder2, Subrata Chakrabarti1
Department of Pathology and Laboratory Medicine, Western University, London,
Ontario, Canada
2
Department of Opthamology, Western University, London, Ontario, Canada

Submitted to Diabetes

109

4.1 Introduction
The prevalence of diabetes mellitus worldwide has increased considerably and is
estimated to rise from 382 million in 2013 to 592 million by 2035 (1). Over time,
diabetes can lead to several life-limiting complications at both micro and macrovascular
levels (2). Diabetic retinopathy (DR) is the most common microvascular diabetic
complication that can cause vision-threatening retinal changes in one-third of the diabetic
patient population (3). Progression of DR is strongly associated with duration of diabetes,
hypertension and hyperglycemia (4). Hyperglycemia has been shown to impair
endothelial function in both animal and human studies (5-7). The endothelial cells (ECs),
lining the entire circulatory system, facilitate effective pumping of blood, secrete factors
to regulate coagulation, fibrinolysis, platelet aggregation and vascular tone, and plays a
critical role in maintaining overall homeostasis (8,9). On exposure to hyperglycemia, ECs
undergo a range of intracellular occurrences that leads to endothelial dysfunction, where
the endothelium loses it physiological properties (9). In diabetes, endothelial dysfunction
promotes excess accumulation of fibrous connective tissue and extracellular matrix
(ECM) proteins in and around the damaged tissue leading to organ dysfunction (10,11).
Abnormal accumulation of ECM is accompanied by local fibroblast proliferation and its
differentiation into myofibroblasts, the key cellular mediators of fibrosis (12). Damaged
ECs also express markers characteristic of myofibroblast differentiation such as α-smooth
muscle actin (α-SMA), smooth muscle 22 (SM22), vimentin and fibroblast specific
protein 1 (FSP1); thereby, adopting a mesenchymal phenotype (8). Concurrently, EC
markers such as vascular endothelial cadherin (VE-Cadherin) and cluster of
differentiation 31 (CD-31) are down-regulated (8). ECs undergo this phenomenon known
as endothelial-mesenchymal transition (EndMT) to gain a differentiated phenotype and
attain invasive and migratory abilities in order to affect pathological processes in
numerous ways (8). EndMT, similar to epithelial–mesenchymal transition (EMT) may be
regulated by TGF-β superfamily of proteins including TGF-β1 and TGF-β2 through
Smad-dependent and Smad-independent pathways such as MEK/ERK, PI3K and
p38MAPK signaling pathways (8, 13-15).
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Long non-coding RNAs (lncRNAs) are RNA transcripts >200 nucleotides in length
lacking protein coding potential (16). lncRNAs are known to play important roles in
physiological processes such as modulation of alternate splicing, chromatin remodeling,
cis/trans-acting regulators of gene expression and RNA metabolism (17-19). Recent
evidences show that dysregulation of target genes lead to abnormal lncRNA expression in
multiple cancer types and they play critical roles in mediating TGF-β-induced EMT
during tumor metastasis (20,21). One of the key lncRNAs in tumorigenesis is the
oncofetal lncRNA, H19. The H19 gene is paternally imprinted and produces a 2.3kb
spliced, capped and polyadenylated lncRNA which is predominantly cytoplasmic and coregulated by Igf2 (Insulin-like growth factor 2); a maternally imprinted gene located on
the same locus (22). The specific role of H19 in tumorigenesis is disputable as it is
known to harbor pro-tumorigenic properties (23) and concurrently, literature describes its
tumor suppressor roles (22,24).
We have previously reported the development of EndMT in the retina and heart of
diabetic animals accompanied by activation of TGF-β-mediated SMAD signaling cascade
and increased expression of ECM proteins (25,26). This glucose-induced phenomenon is
regulated by miRNA 200b (miR200b) through modulation of a histone acetyltransferase,
p300 (25,26). H19 has been shown to alter miR-200 pathway by increasing histone
acetylation upstream of this miRNA; contributing to the reversal of EMT (24). Exposure
to high glucose reduced H19 expression in neonatal cardiomyocytes and in the
myocardium of streptozotocin-induced diabetic rats (27). However, the role of H19 in the
process of EndMT during DR remains unknown.
The purpose of the current study was to decipher the role of H19 in the development of
EndMT during DR. We have used human retinal microvascular endothelial cells
(HRECs) to understand if H19 regulates this phenomenon through TGF-β-mediated
Smad-dependent or Smad-independent pathways and its influence on miR200b during
this process. We further expanded this study to include STZ-induced diabetic mouse
models and vitreous samples from diabetic patients.
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4.2 Materials and Methodology
4.2.1 Cells
HRECs (Olaf Pharmaceuticals, Worcester, MA, USA) were grown in endothelial basal
media-2 (EBM-2) supplemented with 10% fetal bovine serum (25). Cell were plated at
4.3 x105 cells/mL and following 24-hour incubation with serum free EBM-2 media were
treated with various glucose levels (5 mM/L, normal glucose [NG]; 25 mM/L, high
glucose [HG]) for 48 hours. All cells for transfection experiments were seeded at 7.5 x105
cells/mL to achieve 90% confluency. Following transfection, they were serum starved for
24 hours and treated with various glucose levels for 48 hours. Each experiment was
performed with three or more replicates.

4.2.2 Animals
All animals were cared for according to the guiding principles in the care and use of
animals. Western University and Animal Care and Veterinary Services approved all the
experiments and they conform to the guide for care and use of laboratory animals
published by the National Institutes of Health (NIH Publication 85-23, revised in 1996).
H19∆exI mice, generated on a C57/BL6-J background by cre-loxP-based deletion strategy
targeted to delete exon1 from H19, were used for this study along with littermate controls
(28). H19∆exI mice were a generous gift from Dr. Karl Pfeifer at NIH (Maryland, USA).
These mice were administered with streptozotocin (STZ) intraperitoneally. They were
given a total of five doses (50 mg/kg in citrate buffer, pH 5.6) on alternate days (30). Sex
and age-matched littermate controls received identical volume of citrate buffer.
Hyperglycemia was confirmed by measuring tail vein blood glucose (>20 mmol/L) using
a glucometer. All animals were frequently monitored and placed in metabolic cages (24
hours) to collect urine following 8 weeks of diabetes. Afterwards all mice were
euthanized and retinal tissues were collected.
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4.2.3 Human Vitreous samples
The clinical components of this study were approved by The Western Research Ethics
Board at the University of Western Ontario, London, Ontario, Canada. All patients
provided informed consent prior to surgical sample procurement and all samples were
handled according to the Declaration of Helsinki. Vitreous humor (VH) was collected
from patients undergoing a 25-gauge pars plana vitrectomy performed by an experienced
vitreoretinal surgeon. The samples were categorized into diabetic groups comprised of
patients diagnosed with proliferative DR (PDR; n=8; 5 males and 3 females; mean age ±
SD= 76 ± 3.77 years) and non-diabetic groups (n=5; 3 males and 2 females; mean age ±
SD= 61.6 ± 8.35 years) with no previous history of diabetes mellitus and diagnosed with
idiopathic macular hole or a separate non-diabetic ocular condition. All VH specimens
were centrifuged at 12,000g for 10 minutes at 4°C and pellet collected for RNA
extraction as described below (29). Vitreal hemorrhage indications in the VH samples
were excluded from the study to avoid contaminating RNA from blood cells.

4.2.4 RNA analysis
Total RNA was extracted using TRIzol reagent (Invitrogen, Canada) as described
previously (26). cDNA for PCR was produced with high-capacity cDNA reversetranscription kit (Applied Biosystems, Burlington, ON, Canada). Detection of mRNA
expression was performed through real time RT-PCR using LightCycler (Roche
Diagnostics). Housekeeping gene β-actin was used to normalize the data.

4.2.5 miRNA Analysis
miRNA extraction from HRECs were performed using mirVana miRNA isolation kit
(Ambion, Austin, TX, USA). cDNA was synthesized using TaqMan microRNA Assay
Reverse Transcription Primer and MultiScribe reverse transcriptase (Life Technologies,
Canada) following manufacture’s protocol (26). TaqMan microRNA Assay was also used
to perform real time RT-PCR in a LightCycler (Roche Diagnostics). All data were
normalized to U6 small nuclear RNA.
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4.2.6 Fluorescence In Situ Hybridization
In order to perform fluorescence in situ hybridization (FISH), the cells were seeded at
75% confluency on glass coverslips in 12-well plates and treated with various glucose
levels (5 mM/L, normal glucose [NG]; 25 mM/L, high glucose [HG]) for 48 hours as
described previously (30). FISH was performed according to the manufacturer’s protocol
(biosearchtech.com/ stellaris protocols). The human H19 probes were oligonucleotides
tagged with CAL Fluor® Red 610 Dye, mixed and pooled to a final concentration of
5nmol (Biosearch Technologies, Petaluma, CA, USA). The HRECs hybridized with
probes were counterstained with Hoechst and mounted with Vectashield mounting
medium (Vector Labs, Burligame, CA, USA). Images from the stained cells were
captured with a fluorescent microscope (Olympus BX51; Olympus, Richmond Hill, ON,
Canada) and analyzed with ImageJ software (National Institute of Health, Bethesda, MD,
USA).

4.2.7 Immunofluorescence
The HRECs were seeded on a cover slip in 12-well plates at approximately 75%
confluency. Following various treatments the cells were rinsed with PBS and fixed with
methanol:acetone (4:1, vol:vol) and permeated with 0.5% Triton X-100 in PBS (25).
After incubation with 5% normal serum, the cells were incubated with one of the primary
antibodies: mouse anti-CD31 (Abcam, Toronto, Canada), rabbit anti-VE Cad (Santa
Cruz, CA, USA), rabbit anti-FSP1 (Abcam, Toronto, Canada), rabbit anti-SM22 (Santa
Cruz, CA, USA), goat anti-vimentin (Santa Cruz, CA, USA) and rabbit anti-TGF-β
(Abcam, Toronto, Canada) at 1:100 dilutions. The corresponding secondary antibodies
conjugated with Alexa Fluor 488 (goat anti-mouse IgG, goat anti-rabbit IgG or donkey
anti-goat IgG [Invitrogen, Canada]) were used at 1:200 dilutions. A fluorescent
microscope (Olympus BX51; Olympus, Richmond Hill, ON, Canada) was used to detect
and capture the stains and images were analyzed with ImageJ software. Hoechst 33342 (1
mg/mL; Invitrogen) was used as the nuclear stain.
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4.2.8 Luminex Assay
The components of TGF-β signaling were measured using Milliplex MAP TGF-β
signaling pathway magnetic bead 6-plex-Cell Signaling Multiplex assay (Millipore, MA,
USA). The kit comprises of pAkt (Ser473), pERK 1/2 (Thr185/Tyr187), pSmad 2
(Ser465/Ser467), pSmad 3 (Ser423/Ser425), Smad 4 (Total), TGFβRII (Total) analytes.
The cells following treatment, were collected in ice cold 1X MILLIPLEX® MAP Lysis
Buffer with freshly added protease. Particulate matter from samples were removed by
filtration and total protein from the extracted lysate was measured by bicinchoninic acid
(BCA) method. The samples (<500 mg/ml) were assessed using Luminex technology
with Milliplex MAP TGF-β signaling kit containing multiplex magnetic bead-based
antibody detection kit according to manufacturer’s protocol (30).

4.2.9 Statistical analysis
The statistical significance was determined by Student’s t-test or one-way ANOVA
followed by post-hoc test when appropriate. All data were expressed as mean ± SEM and
a p value of 0.05 or less was considered to be significant. All results are expressed as
average of n = 5-8/per group. GraphPad Prism 5 (GraphPad, CA, USA) software was
used for statistical analysis.

4.3 Results
4.3.1 H19 expression is regulated in ECs by exposure to glucose
Our first aim was to study the expression changes of lncRNA H19 in HRECs when
subjected to glucose insults. We had previously performed a microarray analysis on
HRECs exposed to 25 mM D-glucose (HG) for 48 hours to study expression levels of
lncRNAs (30). The results of the array analysis showed one of the highest levels of
downregulation of H19 in HG compared to 5 mM D-glucose (NG) controls (data not
shown). Furthermore, duration dependent analyses of H19 expression showed one of its
lowest levels after 48 hours of HG exposure. We validated glucose-mediated
downregulation of H19 expression in these retinal endothelial cells through measurement
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of H19 RNA expression post-HG treatment (Fig 4.1A). H19 expression was also
visualized in these cells by performing RNA FISH, which helped us to delineate its subcellular distribution. The experiment was performed with oligonucleotide probes for
human H19 that were highly specific, and the technique has been previously performed
by us (30). FISH analyses showed a significant reduction in H19 expression in the HG
treated cells (Fig 4.1B and C). In the control groups (NG), H19 was distributed both in
the nucleus and predominantly cytoplasm. When treated with HG, although both nuclear
and cytoplasmic positivity were reduced, the changes were pronounced in the nucleus. To
examine whether this finding is clinically relevant, we performed similar analyses from
the RNA extracted from vitrectomy samples. We found that H19 RNA expression levels
were significantly lower in the diabetic vitreous samples compared to its controls (Fig
4.1D).
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Figure 4.1: H19 expression in glucose-treated human retinal endothelial cells (HRECs).
(A) H19 RNA expression (Mean±SE) measured using real-time RT-PCR was reduced on
exposure to 25mM glucose (HG, 48 hours). Fluorescence in situ hybridization (FISH)
using human H19 probes showed a decrease in H19 expression (B) in HRECs exposed to
HG with largely cytoplasmic localization in comparison to 5mM glucose (NG) controls.
FISH data quantification (C) performed using ImageJ confirmed glucose-induced H19
down-regulation (MFI- mean fluorescence intensity). RNA analysis of vitreous humor in
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diabetic patients (Diabetic) indicated decrease in H19 levels (D) compared to nondiabetics. (RNA data expressed as ratio to β-actin, normalized to control, * p< 0.05
versus NG or non-diabetics, n=5 or more/group, individual values are represented as dots
or squares).

4.3.2 H19 reverses glucose-mediated EndMT in HRECs and in the
retinas of diabetic animals
The transition from endothelial to mesenchymal phenotype is characterized by decrease
in the expression of endothelial markers and gain of a more mesenchymal phenotype. We
have employed multiple markers to validate this transition. For the endothelial markers,
we used cluster of differentiation 31 (CD 31) and VE cadherin (VE-cad); while the
mesenchymal markers used were fibroblast-specific protein 1 (FSP1), smooth musclespecific 22 (SM22), α-smooth muscle actin (α-SMA), and vimentin. All of these
molecules represent well-characterized markers of EndMT and have been used in
multiple studies including in our previous work (25,26,31,32). HG treatment showed
significant downregulation of endothelial markers; CD 31 and VE-cad (Fig 4.2A and B)
accompanied by upregulation of mesenchymal markers; FSP1, SM22 and α-SMA (Fig
4.2C-E). As the expression of H19 is reduced in HRECs on exposure to HG, we
overexpressed H19 in HRECs to establish a cause-effect relationship. We used a pcDNA
3.1(+) harboring a full-length cDNA sequence of human H19. We transfected the HRECs
with an empty vector (control) or h19-pcDNA 3.1, followed by treatment of cells with
varying glucose concentrations and quantification of mRNA levels by real-time RT-PCR.
Overexpressing H19 reversed the EndMT phenomenon in spite of the presence of HG
environments (Fig 4.2A-E), indicating that glucose-induced EndMT changes are
mediated through H19 in HRECs. As miR200b is a well-known negative regulator of
EndMT (25,26), we conducted a similar experiment with miR200b mimic transfection
followed by HG incubation, confirming its prevention of HG-induced EndMT (Fig 4.2AE).
To identify a relationship of H19 with miR200b in this context, we performed additional
experiments (Fig 4.2A-E). H19 overexpression increased basal and glucose-induced
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miR200b downregulation (Fig 4.2F). In order to delineate a direct relationship, we
performed a rescue experiment. We suppressed miR200b expression using miR200b
antagomirs in NG environment and then overexpressed H19. Such intervention prevented
glucose-induced EndMT suggesting that H19 may also work independent of miR200b
(Fig 4.2A-E).

Figure 4.2: Effect of H19 overexpression on EndMT markers at mRNA level (Mean±SE).
Twentyfive mM glucose (HG) treatment reduced mRNA expression of endothelial
markers [CD 31 (A) and VE cadherin (VE-cad) (B)] and increased expression of
mesenchymal markers [FSP1 (C) and SM22 (D) and α-SMA (E)] compared to 5mM
glucose (NG). Overexpression of H19 (H19 NG and H19 HG) reversed such alterations
of EndMT markers (A-E). Similarly, miR200b overexpression [using miR200b mimics
(200b HG)] corrected HG-induced alteration of EndMT markers. H19 overexpression
increased basal and glucose-induced miR200b downregulation (F) and rescued cells from
EndMT in spite of blockade of miR200b using antagomirs (H19 200b(ant) NG) (A-E).
(mRNA data expressed as ratio to β-actin, normalized to control. *,# p< 0.05 versus
empty vector treated with NG (NG) and empty vector treated with HG (HG) respectively,
n=6 or more/group).
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We extended our study to confirm the changes at protein level. HRECs transfected with
empty vectors and H19 were treated with varying glucose concentrations (NG and HG).
Following the treatments, fixed cells were incubated with fluorescence-tagged antibodies
for endothelial markers, CD 31 and VE-cad, and mesenchymal markers, FSP1, SM22 and
vimentin. In all instances, HG-induced reductions of endothelial markers were corrected
with H19 overexpression (Fig 4.3A-D). Furthermore, similar correction of HG-induced
increase of mesenchymal markers were seen following H19 overexpression (Fig 4.4A-D
and Supplementary Figure) in keeping with the mRNA levels. siRNA mediated silencing
in NG produced a glucose-like effect on EndMT markers. Interestingly, lowering of H19
expression in HG environment did not have any further effects on these markers, which
may suggest that such alterations have already reached lowest biological levels following
HG incubation (Fig 4.5A-E). In the animal experiments, STZ-induced wild-type and
H19∆exI were monitored for 2 months. Elevated blood glucose, polyuria and reduced body
weight were evident in the diabetic animals, indicative of poorly controlled diabetes
(Supplementary Table). Analyses of retinal tissues from these animals showed diabetesinduced, reduced H19 in association with characteristic retinal changes of EndMT,
namely, reduced endothelial and increased mesenchymal markers. All such changes were
further exaggerated in the H19/KO mice (Fig 4.5F-J).
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Figure 4.3: Effect of H19 upregulation on protein expression of endothelial markers.
Immunofluorescence stains of human retinal endothelial cells (HRECs), showed reduced
expression of endothelial markers CD 31 (A) and VE cadherin (VE-cad) (B) in 25mM
glucose (HG) versus 5mM glucose (NG). These alterations were prevented in H19
overexpressed HRECs (H19 NG and H19 HG). Quantification date using ImageJ
confirmed these findings (C and D) (MFI- mean fluorescence intensity. *,# p< 0.05 versus
empty vector treated with NG (NG) and empty vector treated with HG (HG) respectively,
n=6 or more/group).
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Figure 4.4: Effect of H19 on mesenchymal markers at protein level. Immunofluorescence
stains of human retinal endothelial cells (HRECs) showed increased expression of
mesenchymal markers FSP1 (A) and SM22 (B) in 25mM glucose (HG) treated cells
versus 5mM glucose (NG). H19 overexpression downregulated these markers in HRECs
(H19 NG and H19 HG). Quantification data using ImageJ confirmed these findings (C
and D). (MFI- mean fluorescence intensity. *,# p< 0.05 versus empty vector treated with
NG (NG) and empty vector treated with HG (HG) respectively, n=6 or more/group).
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Supplementary Figure: Effect of H19 on mesenchymal marker vimentin protein.
Immunofluorescence stains showed increased expression of vimentin (A) with 25mM
glucose (HG) treatment versus 5mM glucose (NG) in human retinal endothelial cells
(HRECs). H19 overexpression downregulated vimentin in HRECs (H19 NG and H19
HG). Quantification data using ImageJ confirmed these findings (B). (MFI- mean
fluorescence intensity. *,# p< 0.05 versus empty vector treated with NG (NG) and empty
vector treated with HG (HG) respectively, n=6 or more/group).

Table 4.1: Body weight, blood glucose levels and urine volume of all treatment groups.

Supplementary Table: Body weight, blood glucose levels and urine volume in various
groups of mice following 2-month diabetes. (WT-C: wildtype controls, WT-D: wildtype
diabetics, H19KO-C: H19∆exI controls, and H19KO-D: H19∆exI diabetic animals. *,# p<
0.05 versus WT-C or WT-D respectively, n=6 or more/group).
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Figure 4.5: H19 siRNA transfection lead to a glucose-like EndMT phenotype. H19
siRNA transfection of human retinal endothelial cells reduced endothelial markers CD 31
(A) and VE cadherin (VE-cad) (B) and upregulated mesenchymal markers FSP1 (C) and
SM22 (D) and α-SMA (E) in 5mM glucose (NG). No further enhancement of EndMT
was seen when similar transfection was carried out in 25mM glucose (HG). Similarly,
H19∆exI animals (H19KO-C) demonstrated a diabetes-like EndMT phenotype in the retina
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(F-J). No further exaggeration of EndMT was seen when diabetes was induced in the KO
animals. [mRNA data (Mean±SE) expressed as ratio to β-actin, normalized to control.
*p< 0.05 versus scrambled NG (scrNG) or wild-type control (WT-C), WT-D=wildtype
diabetic, H19KO-D= H19∆exI diabetic, n=6 or more/group].

4.3.3 H19 regulates transforming growth factor β to suppress EndMT
As TGF-β is an important regulator of EndMT, we examined the role of H19 in
regulating TGF-β1 levels following glucose treatment (25). H19 overexpression had an
inhibitory effect on TGF-β1 and prevented glucose-mediated upregulation of TGF-β1 at
both mRNA (Fig 4.6A) and protein levels (Fig 4.6B and C). The effect of H19 was not
influenced by the varying levels of glucose. miR200b regulates EndMT through TGF-β1
(25). We confirmed this with miR200b mimic transfection followed by HG incubation
(Fig 4.6A). We also wanted to understand if the regulation of TGF-β1 by H19 is
dependent on miR200b levels. We did so through a rescue experiment, by suppressing
miR200b expression using miR200b antagomirs in NG environment and then
overexpressed H19. The TGF-β1 levels continued to be downregulated in these samples,
further indicating possible H19 action independent of miR200b (Fig 4.6A).
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Figure 4.6: H19 prevents glucose-mediated upregulation of TGF-β1. Twenty five mM
glucose (HG) treatment increased mRNA expression (Mean±SE) of TGF-β1 compared to
5mM glucose (NG) (A). H19 overexpression reduced TGF-β1 both in NG and HG
environments (H19 NG and H19 HG). Similar reduction was seen following miR200b
mimic transfection (miR200b HG). miR200b antagomirs [H19 200b(ant) NG] failed to
rescue H19 overexpression-induced TGF-β1 downregulation. Exposure to HG elevated
TGF-β1 protein expression in HRECs (B). H19 overexpression downregulated the
increase in TGF-β1 protein, on exposure to varying glucose levels (H19 NG and H19
HG). Quantification data using ImageJ confirmed these findings (C). (MFI- mean
fluorescence intensity. *,# p< 0.05 versus empty vector treated with NG (NG) and empty
vector treated with HG (HG) respectively, n=6 or more/group).

4.3.4 H19 regulates TGF-β1mediated EndMT through Smadindependent MAP-ERK 1/2 pathway
We further attempted to identify the signaling pathway affected as a result of H19’s
regulation of EndMT. As we had several potential candidates for TGF-β signaling
encompassing both Smad-dependent and Smad-independent pathways we decided to
utilize Luminex technology. This is a cutting-edge technology that utilizes multiplex
assays that will facilitate simultaneous relative quantification of several phosphorylated
and total TGF-β signaling proteins from cell lysates. HG caused increased production or
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phosphorylation of TGFβRII (total), pSmad 2, pSmad 3 and Smad 4 (total), pAkt and
pERK1/2 proteins (Fig 4.7A-F). The HRECs were also transfected with h19-pcDNA 3.1
vector and treated with NG (H19 NG) and HG (H19 HG). TGFβRII (total) was
significantly reduced following H19 overexpression (Fig 4.7A). Basal levels of SMAD
proteins (pSmad 2, pSmad 3, Smad 4) and pAkt were increased following H19
overexpression (Fig 4.7B-E). However, levels of these molecules in the HG environment
appeared to be unaltered following H19 overexpression. Interestingly, pERK1/2 levels
were significantly downregulated in samples overexpressing H19 irrespective of the
influence of glucose in these groups (Fig 4.7F). This led us to conclude that H19
suppresses glucose-mediated EndMT through regulation of MAP-ERK 1/2 pathway of
TGF-β signaling using a Smad-independent route.

Figure 4.7: H19 regulates EndMT through Smad-independent MAP-ERK 1/2 pathway.
Luminex assay panel for TGF-β signaling was used to quantify several proteins;
TGFβRII (total), pSmad 2, pSmad 3, Smad 4 (total), pAkt and pERK 1/2. These proteins
were upregulated in human retinal endothelial cells when exposed to 25mM glucose
(HG) treatment compared to 5mM glucose (NG) (A-F). H19 overexpression
downregulated the increase in TGFβRII (total), both in NG and HG (H19 NG and H19
HG) (A). Increased H19 levels did not reduce pSmad 2 (B), pSmad 3 (C), Smad 4 (total)
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(D) and pAkt (E) protein levels.

pERK 1/2 protein levels were significantly

downregulated (F) as a result of H19 overexpression in HRECs treated with NG and HG.
(*,# p< 0.05 versus empty vector treated with NG (NG) and empty vector treated with HG
(HG) respectively, n=6 or more/group).

4.4 Discussion
Our current study deciphers the role of lncRNA H19 in regulating diabetes-induced
EndMT changes in HRECs. We report that H19 overexpression can prevent glucoseinduced transition of endothelial cells from endothelial to mesenchymal phenotype
through its regulation of TGF-β1 and subsequent TGF-β signaling though blockade of
MAP-ERK 1/2 pathway. To demonstrate these changes, we conducted experiments using
H19 over-expression vector and H19 silencing siRNA in HRECs in NG and HG
environments. We also found that such regulatory action of H19 occurs independent of
miR200b, a miRNA that we have previously shown to play a regulatory role in diabetesinduced EndMT (25,26). Our animal experiments further confirmed the role of H19 in
retinal EndMT. Our findings from the human vitreous specimens showed a
hyperglycemia-induced downregulation of H19 in PDR compared to non-diabetics.
lncRNAs are known to play important roles in controlling cancer metastasis through
regulation of epithelial-mesenchymal transition (EMT) by targeting multiple signaling
pathways including TGF-β signaling (33). However, their roles in EndMT, are relatively
less studied. The lncRNA MALAT1, a well-known regulator of DR can modulate TGFβ1-induced EndMT in isolated endothelial progenitor cells (EPCs) by negatively
regulating miR145 (34). A recent study revealed that hypoxia-induced EndMT in human
umbilical vein endothelial cells was promoted by the lncRNA GATA6-AS, through
changes in histone methylation (35). Nevertheless, the role of lncRNAs in regulating
hyperglycemia-induced EndMT remain unclear. We have reported for the first time, a
regulatory role of lncRNA H19 in glucose-mediated EndMT through its inhibition of
TGF-β1 and its subsequent signaling pathway. H19 has been well-studied in tumor
biology, but its role in diabetic complications is not certain. Our data is similar to a
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previous study reporting downregulation of H19 in cardiac tissues of diabetic rats (27).
Our FISH analyses revealed that although in normal cells H19 distributed across the cell
cytoplasm and nucleus, HG treatment reduced its expression to few scattered spots
predominantly in the cytoplasm (24). The exact reasons for such sub-cellular changes
observed need further exploration. Moreover, during EMT in certain cancers, TGF-β is
an important inducer of H19 through activation of PI3K/Akt signaling pathway (36).
However, in our study, during EndMT in HRECs, we found a suppressive effect of H19
on TGF-β1 and TGF-βIIR. Overexpression of H19 significantly reduced TGF-β1 levels
resulting in prevention of EndMT in spite of the presence of glucose. Such findings
suggest alternative epigenetic regulatory mechanisms of H19 that require further studies.
Hyperglycemia is the central event leading to micro- and macrovascular pathologies in
diabetes (37,38). ECs lining the blood vessels are exposed to circulating blood glucose
and is the primary cell type to be affected by hyperglycemia insults (38,39). Endothelial
cell dysfunction ensues as ECs lose their quiescence, elude their normal function and
acquire new phenotypes (39). Increasing evidence suggests that ECs can then acquire a
mesenchymal phenotype and start expressing markers characteristic of myofibroblasts,
contributing to the advancement of sclerotic diseases (40,41). In patients with PDR,
fibrotic and inflammatory alterations in the epiretinal membranes are characterized by αSMA-expressing myofibroblasts and inflammatory cells in the stromal compartment (42).
We and others have reported the development of hyperglycemia-induced EndMT during
various diabetic complications (25,26,43). In the present study, this phenomenon was
reproduced in HRECs as we observed decreases in expressions of endothelial markers,
CD31 and VE-cadherin, accompanied by elevation in the expression of several
mesenchymal markers, FSP1, SM22, α-SMA and vimentin, depicting a phenotype
characteristic of EndMT. Furthermore, our animal data demonstrated similar changes in
the retina of chronically diabetic animals, which are further pronounced following H19
knockdown. In addition, vitreous from PDR subjects showed H19 downregulation.
EndMT was originally identified as an embryonic mechanism for cardiac valve
development from ECs of atrioventricular canal (44). It is also involved in angiogenic
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sprouting of postnatal retina, causing mesenchymal cells to be formed at the tips of
vascular sprouts mediated by VEGF-A (45). Recently, EndMT has emerged as an
important contributor in various pathologies, such as organ fibrosis involving heart,
kidney and retina (14,25,26). EndMT is also suggested to influence development of
fibroblasts and myofibroblasts that are responsible for the progression of fibrosis and
advancement of PDR (41). As the involvement of EndMT in several of these pathologies
increases, a number of EndMT-inducing stimuli have been identified, including growth
factors, cell-cell interactions, shear stress, environmental factors like hypoxia and
hyperglycemia and recently epigenetics (46,47). There have been several reports on
epigenetic modifications contributing to EndMT, which is a stable cell-phenotype
alteration (47). These include aberrant promoter methylation (47), histone deacetylase
(HDAC3) mediated repression (49) and several miRNAs as key regulators of EndMT by
targeting the signaling pathways (49). Our previous work has also reported miR200b as a
negative regulator of diabetes-induced EndMT in retinal and cardiac cells and tissues
(25,26).

Data from this study however suggests that H19 may influence EndMT

independent of miR200b. Such pathway needs further characterization.
TGF-β is described as the major regulator of EndMT and harbors pro-fibrotic properties
by inducing and propagating resident fibroblasts (50). As TGF-β1 can mediate both
Smad-dependent and Smad-independent pathways, we investigated whether these
pathways are regulated by H19. Our previous work on epigenetic regulation of EndMT in
DR describes a Smad-dependent regulation of TGF-β1 mediated by miR200b and histone
acetyltransferase, p300 (25). We employed Luminex assay that quantified phosphorylated
proteins of Smad-dependent (pSmad 2 and pSmad 3) and Smad-independent (pAkt and
pERK 1/2) pathways. The analysis showed no effects on Smad proteins and pAkt levels
following overexpression of H19. Conversely, H19 regulated the expression of
phosphorylated ERK 1/2 proteins, suggesting that H19 mediated suppression of EndMT
occurs through Smad-independent pathway. However, we recognize the need for
extended study into the specific pathway affecting the mechanisms involved in such
epigenetic regulation.
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In conclusion, our current data describes a novel role of lncRNA H19 in regulating
EndMT induced by elevated glucose levels.

H19 facilitates this regulation by

suppressing TGF-β1 and its signaling pathways by repressing MAP-ERK 1/2 signaling
pathway. We recognize that additional mechanisms may be in place regulating such
pathways, which warrants further exploration. Nevertheless, our findings open up
possibilities of RNA-based therapies targeting a fundamental glucose-mediated cellular
phenotypic alteration.
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Chapter 5

5 Discussion and future directions
5.1 Discussion
In the research, we examined two specific lncRNAs, ANRIL and H19 and investigated
their influential role in regulating key factors altered during DC. Following initial
identification of ANRIL and H19 alterations by an array, we demonstrated through a
series of experiments that ANRIL is upregulated on exposure to high glucose levels.
ANRIL regulates glucose-mediated VEGF expression in HRECs and STZ-induced
mouse models. This study of ANRIL in DR was also extended to other diabetic
complications, namely DN and DCM. Here we observed that along with VEGF, ANRIL
also influenced the expression of ECM proteins FN and Col1α4. This regulation is at
least in part, driven by ANRIL’s interaction with PRC2 complex proteins and histone
acetylator, p300. These findings were revealed using ANRIL silencing with siRNA in
HRECs exposed to NG and HG environments. Our results were validated in vivo, using
ANRIL knockout animals induced with STZ.
Similarly, we deciphered the role of H19 in regulating important cellular phenotypic
changes in DR. Exposure to high glucose environment downregulated the expression of
H19 in HRECs and retinal samples from diabetic animals. Furthermore, evaluation of
human vitreous established that similar changes occur in human DR. H19 overexpression
was able to prevent glucose-induced transition of ECs from endothelial to mesenchymal
phenotype (EndMT). This phenomenon, well known to be under the regulation of TGFβ1 was regulated by H19’s action on TGF-β1 and subsequent TGF-β signaling though
blockade of MAP-ERK 1/2 pathway. We demonstrated these alterations through
experiments conducted using H19 over-expression vector and H19 silencing siRNA in
HRECs during NG and HG treatments. Additionally, we observed this action of H19 can
occur independent of miR200b, an important regulator of glucose-induced EndMT (1).
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Our animal experiments further established the role of H19 in retinal EndMT during
diabetes.
It has been well established that ECs are primary targets of glucose-induced tissue
damage (2). In ECs, multiple glucose-induced biochemical alterations coverage onto the
cell nucleus and changes gene transcription ultimately producing increased amounts of
cellular macromolecules. It is important to have a better understanding of such cellular
synthetic processes.
Multiple studies have previously been carried out examining specific genetic
abnormalities as causative factors for the development of chronic diabetic complications.
However, such studies have never been able to provide definitive answers (3). On the
other hand, metabolic memory phenomena and legacy effects of diabetes are well
established (4,5). Hence investigations in epigenetics are essential. Epigenetic
mechanisms have several components including DNA and histone methylation, histone
acetylation ubiquitination as well as non-coding RNA (ncRNA) alterations. ncRNAs
include short ncRNAs such as miRNAs and other types such as long ncRNAs (lncRNAs)
that can regulate chromosomal function and gene expression (6). Among these, the role
of lncRNAs are understudied. They have an extensive role in gene regulation and work in
various ways to regulate expression of targets. Their mechanism of action includes posttranscriptional gene regulation by controlling functions like protein synthesis, RNA
maturation and transport. They have also been implicated in transcriptional interference,
induce chromatin remodeling, generate endo-siRNAs, modulate protein activity, alter
protein localization, function as structural components or act as sponges for miRNAs (7).
Based on our research of the two lncRNAs, it appears that ANRIL acts through PRC2
complex and p300 in regulating VEGF and ECM proteins, while H19 regulates TGF-β1
signaling to prevent EndMT transition. Both these regulators function as modulators of
protein activity.
High-throughput deep sequencing approaches have recently enabled transcriptomic
sequencing with greater accuracy (8). This has helped us to identify various different
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types of ncRNAs and quantify their expression in different tissues. Moreover, ncRNAs
have been demonstrated to be key players in gene regulation. An increasing body of
evidence points to the notion that ncRNAs interact with each other and further are coregulated during various pathological conditions (8-10).
Several pathways can regulate the targets under investigation. We have previously shown
that VEGF is regulated by miR200b, histone acetylator p300 and PRC2 complex (11,12).
Our current research has demonstrated another layer of regulation of VEGF in this
pathway. We have shown that ANRIL through interaction with miR200b, p300 and
PRC2 complex mediate VEGF production. These data for the first time demonstrated
such role of ANRIL in the context of diabetic complications. However, in other systems
ANRIL has been shown to specifically bind to PRC proteins and regulate histone
modification (13). Similar regulations of ECM proteins FN and Col1α4 through ANRIL
were demonstrated in this research in kidney and heart tissues in diabetes. It is of further
interest to note that some of these actions of ANRIL were also mediated by p300. We
have previously demonstrated that p300 regulates a large number of transcripts which are
induced by glucose (14). Hence p300’s regulation by ANRIL may at least in part provide
explanation for regulation of multiple seemingly diverse transcripts that are altered by
glucose.
Similarly, for the first time we demonstrated the role of H19 in DR. H19 has been
previously shown to be downregulated in neonatal cardiomyocytes exposed to high
glucose and myocardium of STZ-induced diabetic (15). In tumor models like
hepatocellular carcinoma, H19 has been shown to alter miR-200 pathway by increasing
histone acetylation upstream of this miRNA; contributing to the reversal of epithelialmesenchymal transition (16). Similar to ANRIL our finding with respect to H19 further
identified another piece of this puzzle.
As mentioned earlier, in our work we have observed ANRIL’s interaction with miR200b.
However, ANRIL can also be a regulator of H19. This was evident in our in vivo and in
vitro experiments where nullifying ANRIL expression led to recovery from glucose and
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diabetes-induced reduction of H19 levels. Furthermore, H19 knockdown in low glucose
environment lead to a glucose-like effect as evidenced by a tendency towards increased
ANRIL expression. Retinal tissues of H19KO animals further showed slight reduction of
ANRIL levels. Interestingly, in additional cell culture experiments, H19 overexpression
led to an inclination towards reduced ANRIL expression (Figure in Appendix I). Hence a
regulatory relationship exists between these two lncRNAs. Additional investigations are
needed to further decipher the exact mode of interaction and subsequent effects.

Figure 5.1: Diagrammatical representation of the key findings of this study

A recent evaluation of literature by Schwartz and colleagues suggests that a key element
of all vascular diseases could be unresolved vascular remodeling (17). It raises the
prospect of restoration of normal modeling as an approach to treat multiple pathological
states. In diabetes, vascular remodeling is hypertrophic and inward as manifested by
increase in the outer lumen diameter with accompanying decreased inner lumen diameter.
Such remodeling in diabetes is driven by endothelial dysfunction and complex signaling
pathways, leading to structural alterations of the arteries and tissue hypoperfusion and
hypoxia (18-21). These events are attributed to the adverse effects of exposure to high
glucose and oxidative stress on the vascular system. The remodeling vasculature in
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contrast to stable blood vessels are associated with VEGF secretion by cells of ischemic
tissues to instigate angiogenesis accompanied by metalloprotease secretion, ECM
degradation accompanied by assemblage of temporary matrices and changes to key EC
signaling and gene expression pathways (17,22). These events are attributed to the
adverse effects of exposure to high glucose and oxidative stress on the vascular system.
Oxidative stress due to increased production of ROS disrupts numerous mitochondrial
and other intracellular pathways, which are associated with increase oxidants produced
and reduction in antioxidant defenses (23). The disrupted normal function of the
mitochondria results in blockade of insulin signaling and activation of NF-kB, resulting
in increased vascular inflammation (24,25). During these inflammatory conditions,
mediators like IL-1β, TNF-α and NF-kB contribute to endothelial dysfunction by
activating ECs and converting them to mesenchymal-like cells through EndMT (26).
EndMT has emerged as a participant in process of tissue fibrosis in various diseases
including DC and mostly induced by TGFβ signaling pathway. The transformed ECs
increase levels of altered ECM and have higher vascular permeability thereby compelling
further inflammation (17). These incidents create a positive feedback loop- EndMT
triggers inflammation and vice versa (17). These developments mediated by TGF-β
further promote fibrosis, which is generally irreversible. Such feedback loops hinder
restoration of a normal vasculature and forces endothelium to maintain its remodeled
state, leading to disease progression (17). Thus, it is important to break the feedback loop
to restore a normal model state as an effective approach to treat multiple vascular
diseases. Hence an understanding of regulation of the production of cell damaging
molecules at every level is essential. The data generated in this research further validates
this hypothesis and contributes to better understanding of this process. We have described
ANRIL’s regulation of VEGF and ECM proteins as well as H19 playing a role in EndMT
as examples of multiple targets regulated by lncRNAs under pathological high glucose
conditions. However, additional large-scale and long-term studies are needed to further
expand current findings.
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5.2 Conclusion
Today more diabetics face morbidity and mortality due to chronic complications. Hence
there is a need for specific therapeutic approaches for diabetic complications. This can
only be achieved by better understanding of the pathogenic mechanisms. In this study, we
have shown novel roles of lncRNAs, ANRIL and H19 in regulating key molecules
(VEGF, ECM proteins FN and Col1α4) and cellular phenotypes (endothelial to
mesenchymal transition) altered during diabetic complications. This understanding can
contribute to further development of RNA-based or other epigenetic mechanisms-based
therapies for chronic diabetic complications.

5.3 Limitations of the study
Although the study has achieved its aims, we understand that there are no studies without
limitations. This study has predominately focused on short-term T1D diabetes and we
have formulated our work with ECs and animal models around short-term diabetes (48
hours and 2 months, respectively). We are yet to decipher the roles of these lncRNAs
under conditions of long-term T1D. Furthermore, we haven’t looked at the role of these
lncRNAs in T2D, although genomic-wide study of ANRIL has identified it to be a
hotspot for T2D (15). We were unable to extent our study past T1D due to time
limitations of this thesis and feel that it is one of the first topics to be addressed in future
studies.
Furthermore, some specific mechanisms need additional investigations. In our study, we
have shown that ANRIL binds to both EZH2 (PRC2 complex) as well as p300 and
positively regulates these proteins. However, p300 is histone acetylator and is known to
activate gene expression, whereas EZH2 is a histone methyltransferase predominantly
know to act as a negative regulator of gene expression. Therefore, ANRIL’s regulation
on EZH2 may additionally involve other factors and pathways, eventual leading to
activation of gene expression. Hence the pathway of ANRIL’s regulation of EZH2 needs
to be further exploration.
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We have employed an H19 knockout (KO) mouse model for elucidation of H19’s role in
DR. We acknowledge that use of a knockout model for an lncRNA that is downregulated
under high glucose conditions is not the best approach. However, STZ- induced H19KO
mouse models were helpful in understanding the effect of further reduction of H19 under
high glucose. H19 overexpressing mouse models are rare and usually involve ectopic
expression of H19 in nude mice, mostly suitable to study tumorigenic potentials of cells
like in heptocellular carcinoma (27, 28). However, the transgenic mice that overexpress
H19 shows several phenotypic changes eg. smaller birth weight and embryonic growth
retardation at E16.5. This was due to H19’s regulation of a network of imprinted genes
(IGN) including Igf2 (Insulin growth factor 2). Igf2 is known to share with H19,
important regulatory elements important for imprinting (29). Hence development of H19
overexpressing mouse models continues to be a challenge and at the current stage such
animals were deemed unsuitable for our study.
Another limitation would be possible off-targets effects of lncRNA knockouts in the
mouse models. Although, we were unable to observe any such effects in the various
tissue sections of the animals, but the possibility of small off target effects that were not
obvious can’t be completely excluded.

5.4 Future direction
Based on the limitations mentioned above we plan to extent our study to additional longer
time points and in other types of diabetes. The mechanism of action of the lncRNAs
described here are part of the big picture, many segments of which needs to be
deciphered through careful and well-designed experimental studies. We also
acknowledge that there could be other factors, such as other lncRNAs playing roles in
these regulatory mechanisms that need further elucidation. They will eventually play
specific roles in together combatting chronic diabetic complications.
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